(more announced soon)
Scott will join his team of exclusive sponsors to host the Emerging Medtech Summit. Scott's mission at the meeting will be to connect the investors, innovators and strategics that are driving the future of medtech.
Scott is the President, CEO and Founder of Life Science Intelligence. He has been in the medtech market intelligence business for over 20 years supporting venture funded startups, major strategics, and life science investors as they navigate the ever-changing medtech marketplace. Prior to founding LSI, he held senior executive roles with renowned life science data providers including Medical Data International, Medtech Insight and Windhover Information. He has held leadership roles as a strategic partner for Elsevier Business Intelligence, Health Research Intelligence, and Informa Business Intelligence. Scott and his team at LSI have conducted numerous market research projects for top medical device manufacturers including Johnson & Johnson, Medtronic, Boston Scientific, Abbott, Becton Dickinson, Teleflex, Cardinal Health, GE Healthcare, and Stryker, among others.
Atul Butte, MD, PhD
Priscilla Chan and Mark Zuckerberg Distinguished Professor & Inaugural Director of the Bakar Computational Health Sciences Institute, UCSF
Chief Data Scientist, University of California Health System
Atul Butte, MD, PhD is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and inaugural Director of the Bakar Computational Health Sciences Institute (bchsi.ucsf.edu) at the University of California, San Francisco (UCSF). Dr. Butte is also the Chief Data Scientist for the entire University of California Health System, the tenth largest by revenue in the United States, with 20 health professional schools, 6 medical schools, 6 academic health centers, 10 hospitals, and over 1000 care delivery sites. Dr. Butte has been continually funded by NIH for 20 years, is an inventor on 24 patents, and has authored nearly 300 publications, with research repeatedly featured in the New York Times, Wall Street Journal, and Wired Magazine. Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the Obama Administration as a White House Champion of Change in Open Science for promoting science through publicly available data. Dr. Butte is also a co-founder of three investor-backed data-driven companies: Personalis (IPO, 2019), providing medical genome sequencing services, Carmenta (acquired by Progenity, 2015), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children's Hospital Boston, then received his PhD from Harvard Medical School and MIT.
Daniel Hawkins is the founder and CEO of Avail Medsystems, a medical technology company creating a network where medical expertise sharing can occur between healthcare professionals and experts to and from the operating room anytime, anywhere.
Over the past 25 years in the medical technology field, Daniel’s mission has been to identify and close gaps that prevent patients from getting the best possible healthcare. He is an inventor on over 140 patents and applications, and has held roles in both large and emerging companies, including Advanced Cardiovascular Systems, Inc., Endologix, Restore Medical, EnteroMedics, and Intuitive Surgical. Daniel is a co-founder of Calibra Medical, acquired by Johnson & Johnson, and founder of Shockwave Medical, Inc. (NASDAQ: SWAV).
Daniel has an MBA from Stanford University and a BS in Economics from The Wharton School of the University of Pennsylvania. In 2017, Daniel was honored by Goldman Sachs as one of its Top 100 Most Intriguing Entrepreneurs.
Chairman & Managing Partner
Antoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997.
“Life Sciences investing is not just about recognizing good science,” Papiernik says, “it’s about people — learning how to interact with co-investors, limited partners, and entrepreneurs. Listening, discerning, negotiating, and finding common interests.”
When you find the right people to invest in, he adds, “you can bank on them more often than you can predict how the science is going to turn out.” He looks for entrepreneurs with the nimbleness to adapt, “even if that means a making a major shift from where one starts out on the journey.”
Antoine actively invests for our Capital Funds. He has been an initial investor and active board member in a number of public companies, including Actelion, ProQR, Shockwave Medical, NovusPharma (sold to CTI), Movetis (sold to Shire), and Pixium Vision. Trade sale success stories include CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis), Ethical Oncology Science (EOS, sold to Clovis Oncology) and Recor Medical (sold to Otsuka).
He has also invested in and is a board member of private companies Reflexion Medical, Tissium, Pi-Cardia, SafeHeal, Noema Therapeutics, Ablacare, Highlife and Inspirna (formerly Rgenix).
Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. He has been selected twice for the Forbes Midas List, an annual ranking recognizing the world’s top venture capital investors. Antoine is one of the few European and life science investors to have appeared on the prestigious list.
Chief Development Officer
Johnson & Johnson Robotics
Fred Moll is a visionary in the healthcare industry and has been called “the father of robotic surgery” – his inventions have helped pave the way for improved surgical procedures for decades. Fred is currently the Chief Development Officer of Johnson and Johnson Medical Devices Companies. A serial entrepreneur, Fred co-founded Intuitive Surgical, Inc. (NASDAQ:ISRG), Hansen Medical (NASDAQ:HNSN), Restoration Robotics (NASDAQ:HAIR), and most recently was the founder and CEO of Auris Health (acquired by J&J April ’19 for $5.75B).
His innovation career began during medical training when he invented the safety trocar, which helped create the field of modern laparoscopic surgery.
Fred is a distinguished speaker and lecturer, a prolific inventor and is the author of numerous scientific articles. He currently serves on the boards of several healthcare companies, including Procept BioRobotics, ShockWave Medical, GI Windows, and RefleXion.
Co-Founder and CEO
Health technology executive with extensive experience developing disruptive technology and creating new markets. Passionate about early stage ventures, entrepreneurship, and intrapreneurial efforts that require market analysis, needs assessment, product and business model discovery and definition, corporate strategic planning, and go-to-market execution.
Managing Board Member
As a member of the Managing Board of a global innovation leader in healthcare, I have the honor, responsibility, and pleasure to drive better access to high-quality care for more people around the world. Thanks to our unique capabilities in patient twinning, precision therapy, digital data, and AI, we’re strategically positioned to help healthcare systems achieve better patient outcomes.
As a leader and builder of innovative healthcare companies like Cognito Therapeutics, Cognoa, and WellnessFx as well as being a part of the healthcare venture investment team at Morningside, I have worked with teams to build therapeutic and device companies that develop novel medicines or Digital Therapeutics (DTx) to address unmet medical needs. I am most interested in companies who I feel can leverage novel approaches to address unmet medical needs and underserved patient populations.
Serial life science entrepreneur and innovator dedicated to globally commercializing world changing medical technologies. Leadership experience from early idea stages through global product launches in both private and public companies, with significant domestic and international management experience.
Confirmed Investors & Strategics
(prelim sneak peek)
Nicole J. Walker
Healthcare Innovator, Board Director, Venture Investor & Advisor
29 years of extensive global experience as a MedDevice and MedTech Executive and Investor. Adept at Investment, General Management, Mergers & Acquisitions, Finance and Corporate Strategy. Passionate about transforming businesses through growth and innovation, developing talent, optimizing resources, creating enterprise value for shareholders, developing new products and executing strategic initiatives to deliver top line growth and increase profitability.
Medical Device Investor/Managing Director
Executive leader with strong experience and success in early stage as well as Fortune 500 health companies. Most recent operating role was President and CEO of Nuelle, Inc., a women's consumer health company (acquired). Currently Managing Director at KCK Medical Technologies Investment Group. Director/Board Chair/Exec Chair of Aerin Medical, Sonex Health, Revelle Aesthetics, Candesant Biomedical and Barologics within KCK portfolio. Independent Board Director outside of KCK in consumer health. Interests: Women's health, Consume
Business Development & Strategy Executive
Piper / Sandler
Founder & Managing Partner
Lu Zhang, Founder and Managing Partner of Fusion Fund, is a renowned Silicon Valley investor, a serial entrepreneur, and a Stanford Engineering alumna. Lu is a World Economic Forum - Young Global Leader. She has also garnered other accolades including the Featured Honoree in VC of Forbes 30 Under 30, Silicon Valley Women of Influence, Town & Country 50 Modern Swans – Entrepreneurship Influencer, and was recently selected as the Best 25 Female early-stage Investor by Business Insider (2021). Prior to starting Fusion Fund, she was the Founder and CEO of a medical device company (acquired in 2013). Lu is a frequent speaker at tech events and conferences such as Davos World Economic Forum, Future Investment Initiative (FII), Forbes, Web Summit, SuperReturn, etc., and serves as a mentor and advisor to several tech innovation programs in Silicon Valley. Lu is the board member of the Youth Council of Future Forum and Future Science Award. Lu is also on the Jury Board of Cartier’s Young Leader Award. She received her M.S. in Materials Science and Engineering from Stanford University.
Jay Watkins has over 30 years experience founding and funding healthcare companies. Jay’s career in healthcare began when he co-founded Origin Medsystems, a venture funded medical technology start-up that was acquired by Eli Lilly & Company and later spun out as part of Guidant Corporation (NYSE: GDT).
He served as president of several Guidant divisions, led its global business development activities, and later served as a managing director at DeNovo Ventures. Jay lectures at the Stanford Graduate School of Business and at the Stanford Byers Center for Biodesign.
He is widely sought after for his strategic insight and knowledge of structuring M&A transactions and currently serves on the boards of several healthcare companies, including Shockwave Medical (NASDAQ: SWAV), Avail Medsystems, RefleXion Medical, Tissium and Neptune Medical.
Managing Director, Business Development
Silicon Valley Bank
Former litigation attorney - have been involved in Healthcare since 1999. Focused on debt and equity strategy for BioPharma, Device, Dx/Tools and Digital Health. Have written numerous thought pieces detailing the flow of capital into venture healthcare (investment and fundraising) as well as M&A and IPO activity.
I am a Managing Director in the Healthcare Practice at SVB, where I run Business Development on the West Coast, and mange Venture Capital relationships. I help investors understand and analyze historical and current market trends around investments and returns, and assist CEOs and C-level management with equity and debt strategy, business plans, exit comps and access to capital.
Chairman of the Board
Front Foot Ventures
Huennekens has more than 25 years of experience in the medical device industry, specializing in clinical advancement through innovative R&D and technology-based initiatives. He currently serves as Executive Chairman of the Board for Acutus Medical (IPO in 2020). He has held a number of executive leadership roles within the healthcare industry, accelerating the next generation of digital surgery for Verb Surgical and leading Volcano Corporation, an image guided therapy device company, to its IPO in 2006. He holds an MBA from Harvard University and a BS in Business Administration from the University of Southern California. Huennekens currently sits on the boards of public companies Viewray and NuVasive.
Founder, Member Board Of Directors, Central and North Florida Chapter, Alzheimer's Association®
Vice President, Business Development & Strategy
Chris Eso currently has dual responsibility as Vice President of Business Development & Strategy for both the Structural Heart & Aortic operating unit and the Cardiovascular Portfolio, which includes eight cardiovascular operating units across Medtronic. Chris joined Medtronic in 2011 and has held numerous business development, M&A and strategy positions of increasing responsibility and scope over his tenure at Medtronic in both the businesses and corporate functions.
Chris brings more than 25 years of successful professional business and general management experience within the pharmaceutical, biotech and medical device industries, in addition to Medtronic, including Allergan, Watson Pharmaceuticals, Agilent Technologies, and Peregrine Pharmaceuticals. Most of his experience is in a business/corporate development and strategy capacity where he has led more than 50 transactions with consideration of approximately $15 billion, as well as general management capacity running a $50 million revenue-generating wholly-owned subsidiary of a publicly-traded company
Chris holds an MBA from Concordia University and BA in Public Relations, Communications from California State University, Fullerton.
Vice President and Chief Innovation Officer
Children's National Health System
Director, Business Development, Venture Capital Investments
Business Development, Venture Capital Investment, Mergers & Acquisitions, Sales Management, and Marketing in Medical Device
Specialties: Venture Capital Investment, Mergers and Acquisitions, Market analysis and business plan development for emerging technologies; upstream market strategy, sales management and team leadership; sales team training and development.
EVP Strategic Partnerships
As Executive Vice President, Strategic Partnerships, Lisa leverages her global product commercialization experience to help forge long-term collaborations with a core focus on Veranex’s strategic partners and their portfolio management.
Lisa has 25+ years of healthcare product commercialization with companies in the U.S., Europe, and China, with a special emphasis on MedTech innovation. As an active member of the MedTech and investor communities, Lisa is an advisor to many startups and accelerators including CLSI’s FAST program, MedTech Innovator, and UCSF Health Hub. She also serves as an advisor to the Cleveland Clinic MedTech Advisory Board, the Mayo Clinic’s Executive Steering Committee for the Surgical Innovation Summit, UCLA Biodesign, UCLA’s Technology Ventures Group Advisory Board, and RedCrow Angel Investor platform. Lisa serves on the Board of Directors for MarinHealth system, a partner of UCSF and is Co-Chair of MedtechWomen’s Annual MedTech Vision Conference in 2021-22. Lisa has a keen interest in the latest MedTech innovation trends and authors Veranex’s MedTech Pioneers blog, which spotlights MedTech leadership and their groundbreaking work.
Vice President, Strategy & Business Development
Thermo Fisher Scientific
Global executive with more than 15 years of experience in the healthcare industry, leading mid-to-large size multinationals in the areas of business development, strategy and M&A. Experienced at leveraging inorganic growth to build sustainable businesses while further developing the organizational capabilities and the innovation pipeline of the organization. Team player used to leading in international multi-decision level environments through a focus on addressing change management, collaboration, and efficient decision-making.
Kevin Chu is a Principal on the healthcare team at F-Prime Capital. Prior to F-Prime Capital, Kevin was an Associate Consultant with IMS Consulting Group in New York, where he advised biopharmaceutical clients on development and commercial strategy across multiple therapeutic areas.
Kevin is currently based in the San Francisco office, and works across the healthcare sub-sectors including Therapeutics, MedTech, and Healthcare IT and Services, and also works closely with Eight Roads Ventures China healthcare team to manage F-Prime’s existing and new investment efforts in China.
Director, Stanford Biodesign and Special Partner
Josh is a Special Partner on NEA's healthcare team and has worked closely with NEA since his time as an EIR back in 1995, stepping up as a General Partner to lead our medtech/healthtech practice from 2015 to 2021. In addition to his continuing role at NEA, Josh serves on the faculty of the Stanford University Medical and Engineering Schools as a Professor of Medicine and Bioengineering and is Director and Co-Founder of The Stanford Byers Center for Biodesign. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 9 companies over the past 25 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009, EndoMatrix, acquired by C.R. Bard in 1997, TransVascular, acquired by Medtronic in 2003, Nuelle, acquired by AyTu Biosciences in 2014, and Neotract acquired by Teleflex in 2017. On-going ExploraMed/NEA ventures include Moximed, Willow Innovations, Revelle Aesthetics, and ExploraMed V. Josh currently serves on the boards of Eargo (NASDAQ: EAR), Allay Therapeutics, Lungpacer, Revelle Aesthetics, Magenta Medical, DOTS Technology Corp., ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint Medical, Willow and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, aesthetics, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor's degree in Mechanical Engineering from MIT, and is a Fellow of the American Institute of Biomedical Engineering and a member of the National Academy of Engineering.
Mr. Bikoff is a Principal at Longitude Capital. Prior to joining Longitude Capital in 2016, Mr. Bikoff held a series of strategy, finance, and operating roles at Cardinal Health. While at Cardinal Health, he worked to deploy over $6 billion of capital through M&A and minority investments. Most recently, Mr. Bikoff was the Director of North America Marketing for the Cordis cardiovascular franchise. Mr. Bikoff currently serves on the board of Polares Medical and is a board observer at Ceribell, Endogenex, Limflow, and Nalu. He previously served as a board observer at Amphora (acquired), Eargo (EAR), and RxSight (RXST), and was also actively involved in Longitude Capital’s investment in Axonics Modulation Technologies (AXNX) and PROCEPT BioRobotics (PRCT). Mr. Bikoff began his career in Deloitte Consulting’s Life Sciences Strategy practice and holds a BSE in Biomedical Engineering from Duke University.
Vice President, Business Development
David Greenwald, Ph.D., is a Vice President, Business Development on the Therapeutics team and joined the Firm in 2018. In this role, Dr. Greenwald is responsible for searching for new investment opportunities, supporting business development of Deerfield private portfolio companies, and providing his expertise to Deerfield’s research collaborations and venture creation efforts. Prior to joining Deerfield, Dr. Greenwald was the Director of Business Development at Johns Hopkins Technology Ventures. He was a co-founder and Chief Executive Officer of Relay Technology Management, Inc. and a co-inventor of the Relay Innovation Engine software platform. After Relay was acquired by Decision Resources Group, Dr. Greenwald served as the Director of Client Solutions at Decision Resources Group. Before that, he was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD, where he worked on developing diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland, College Park and earned his Ph.D. in Genetics from Tufts University. Dr. Greenwald currently serves on the Boards of Jaguar Gene Therapy, Axovia Therapeutics, and Apertura Gene Therapy.
Chief Scientific Officer & Corporate Vice President
Todd J. Brinton, M.D., has been corporate vice president, advanced technology, and chief
scientific officer, since 2019. Dr. Brinton has significant experience as a champion of
cardiovascular innovation and has a strong patient focus as a tenured practicing clinical
cardiologist. He has deep ties to the medical technology community as a founder, board
member and advisor to several start-up companies, including his role as physician founder,
board member, and chief medical officer of ShockWave Medical, Inc. Dr. Brinton began his
career as an engineer in the medical technology industry, ultimately becoming a director of
clinical research and development, prior to entering medical school. Before joining Edwards, he
was a clinical professor of medicine (cardiology) and adjunct professor of bioengineering at the
Stanford University School of Medicine. He was an attending interventional cardiologist at both
the Stanford University Medical Center and the Palo Alto VA Medical Center. Dr. Brinton also
served as the fellowship director at the Stanford Byers Center for Biodesign from 2006 to 2019,
where he mentored and directed numerous teams on the development of new technologies. In
addition, he served as the co-director for both the graduate and executive education programs
at the center during a similar time period. He is extremely active in the American Heart
Association serving as the Chair of the 2022 Bay Area Research Roundtable and the 2022
Orange County Heart & Stroke Ball. In addition, he currently serves on the AHA national
research committee and strategic outcomes subcommittee. He has served on the advisory
board for the Edwards Lifesciences Foundation Cardiovascular Innovation and Research Center
at UC Irvine since 2020. Dr. Brinton received his bachelor’s degree from the University of
California, San Diego in biomedical engineering, and his medical degree from the Chicago
Medical School at Rosalind Franklin University. He completed his internship, residency, and
fellowships in cardiology and interventional cardiology at Stanford.
Fouad Azzam, Ph.D.
EQT Life Sciences
Fouad Azzam is a Partner in the EQT Life Sciences team. Fouad worked for LSP from 2007 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences.
Prior to joining LSP, Fouad worked as a Managing Director Eastman Ventures and Director at Eastman Chemical Company in Kingsport TN, USA. Prior to Eastman Chemical Company, Fouad was part of the Research & Business Development group at Occidental Chemical Company in Grand Island NY, USA.
Fouad holds an Ph.D. in Chemical Engineering from the University of Akron, USA and an M.B.A. from SUNY Buffalo, USA.
Wells Fargo Strategic Capital
Prior to joining HealthpointCapital, Milen Todorov was a Director in the global healthcare team at UBS Investment Bank, focusing on the musculoskeletal sector. While at UBS, Milen executed over 25 M&A and capital raising transactions with aggregate value in excess of $35 billion. He began his career in economic litigation consulting at Charles River Associates. Mr. Todorov received a B.A. in Economics from Middlebury College and an MBA from the Tuck School of Business at Dartmouth.
Senior Venture Partner
Dr. Azin Parhizgar served as Chief Executive Officer, President and Board Member at Claret Medical. She is an experienced and successful medical device industry executive and entrepreneur. Prior to Claret Medical, she served as the Chief Operating Officer of Conor Medsystems which led to the acquisition of the company by Johnson & Johnson, Inc. in 2007. She spent one year post-merger with Johnson & Johnson for full integration of the companies. Between 1996-2000 she held the position of Executive Vice President for Arterial Vascular Engineering, which was acquired by Medtronic. She spent two years at Medtronic post-merger in increasing roles of responsibility leading to her role as Executive Vice President of Emerging Ventures and New Technologies. Dr. Parhizgar has served as an advisor to emerging medical device technology companies including several Board of Directors and Scientific Advisory Board positions. Dr. Parhizgar received both her Ph.D. in Cell, Gene and Tissue Engineering and her M.Sc. in Biomechanical Engineering and Artificial Organ Design from Brown University.
Frederik is a Co-Founder and General Partner of 415 CAPITAL. He has been an investor in more than a dozen of innovative medical technology companies and led 415’s investments in Supira Medical, CorFlow Therapeutics, Cardiac Success, Aktiia, Distalmotion and R3 Vascular. He currently serves as a Board Director at Cardiac Success and R3 Vascular. Prior to co-founding 415 CAPITAL, Frederik served as Business Development Manager at Regis Medical, a Germany based medical device distributor where he helped source and evaluate new partnerships and investment opportunities. Previously, Frederik worked in HSBC’s Leveraged & Acquisition Finance group in New York City where he structured financings for private equity-backed buyouts and corporate M&A transactions including several large-cap Healthcare transactions. Before moving to New York City, he was an Analyst at HSBC in London where he advised clients on cross-border M&A transactions and IPOs. Frederik holds an Hon. B.A. in Economics magna cum laude from the University of Toronto (University College), Canada.
Frank has almost 40 years of investing, management, sales & marketing experience in the MedTech space, the last 30 years as serial investor and entrepreneur. As an investor, he has funded over 40 MedTech companies. As an entrepreneur, he has founded, built, and exited several successful European MedTech distribution companies, including Regis Medical GmbH, Ovum Ventures GmbH (sold to Medtronic in 2009) and Cardiologic GmbH (sold to Boston Scientific in 2002). His companies have commercialized over 20 novel medical device technologies in Europe and helped establish new clinical standards of care, including cerebral embolic protection, transcatheter aortic valve replacement (TAVR), ultrasound renal denervation, and the world’s first pre-mounted coronary stents (Arterial Vascular Engineering). Following Boston Scientific’s acquisition of Cardiologic GmbH, Frank served as the General Manager of Boston Scientific’s Interventional Cardiology Division Germany. Previously, he held several management positions at St. Jude Medical (now part of Abbott), Inc., W. L. Gore & Associates, and AHSC American Hospital Supply Corp. (now part of Baxter).
TVM Capital Life Science
Sascha Berger, PhD, joined the TVM Capital Life Science team in Munich in 2016. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as corporate finance aspects of the fund.
Sascha has a strong financial background with almost ten years of professional transaction and strategy experience. He has a track-record of concluding 20 M&A transactions, five of those he led as responsible project manager in his previous role as Senior M&A Manager in a PE backed global corporation. He was a core team member in a successful EUR 2.5bn revenue cross-border merger and successfully coordinated global merger clearance procedures (USA, China, EU, Korea).
Prior to this recent role, Sascha successfully advised multiple renowned clients in corporate finance and strategy projects working as (senior) consultant for PricewaterhouseCoopers and the Boston Consulting Group. He was selected for the global leadership development program in his previous role and was named a global high-potential in PwC.
Sascha studied technology management in Munich, Singapore and Boston and holds a Master from Munich University of Technology with majors in entrepreneurial finance and chemistry, magna cum laude. In his master thesis he analyzed the specific challenges of biotech VC financing rounds. Later he completed his PhD studies in banking and finance while already working for PwC. He is a regular speaker on corporate finance topics for German universities and business schools.
During his studies he already supported TVM Capital Life Science part-time; he supported the IPO of a German technology company at Deutsche Bank and advised Private Equity funds at Deloitte in summer internships. He lived in Singapore and New York, co-founded a student initiative on Entrepreneurship in Munich and in his spare time enjoys triathlon and world travelling.
Director & Chief Operating Officer
Genesis Innovation Group
Matt is an entrepreneurial business leader with 15 years of experience in building and managing dynamic technology companies.
He has a proven track record of successfully bringing innovative products and services to market.
Prior to Genesis Innovation Group, he was COO of Conpoto, and VP of Finance, COO and President of LeanLogistics.
President & CEO
Ramin Mousavi is a dynamic executive with an outstanding history of building high-performing teams and achieving exceptional results in the medical device and high-tech industries — from developing to launching and commercializing breakthrough and transformational products. He is currently the President & Chief Executive Officer (CEO) of CathWorks, an innovative global medical device company focused on transforming the diagnosis and treatment of coronary artery diseases. CathWorks is dedicated to improving the care of patients suffering from coronary artery disease by providing clinicians the most comprehensive and objective data through CathWorks digital health platform, a combination of advanced algorithms, artificial intelligence, machine learning and cutting-edge user interface. A rising star of the medical device industry, Ramin has executive leadership and operational experience in general management, marketing, strategy, product development, and commercialization across multiple market segments. Prior to CathWorks, Ramin led the patient monitoring and digital health portfolio at Baxter International. Previously, he held various leadership assignments at Edwards Lifesciences, Panasonic, and Rockwell Collins.
Lead, Digital Surgery, Robotics, DePuy Synthes
Johnson & Johnson
Tyler J. Stowater is Partner and Vice President of Bluestem. He graduated from South Dakota State University with a BS Degree in Agriculture Economics (1984) and a MS Degree in Economics (1986). Tyler spent eleven years with the State of South Dakota's Bureau of Finance and Management. During his tenure, Tyler held the position of budget analyst, state economist, and deputy commissioner. In 1997, Tyler left the State to become an Assistant Vice President at Citibank South Dakota with business analysis responsibilities in the North American Cards Customer Service Unit. Tyler joined Bluestem in 2000 and is currently in charge of portfolio management with responsibilities including the evaluation of prospective companies, structuring, negotiating, and performing due diligence for various investments made by Bluestem. He monitors and provides assistance to existing portfolio companies and holds multiple Board of Director positions. In the spring of 2016, Tyler was given the Distinguished Alumnus award at the 62nd Annual Celebration of Excellence in Economics at South Dakota State University. Tyler is married to Joni (Klosterman) and they have two children, McKenzie (Otterberg) and McCord.
Board of Managing Directors
Heraeus Holding GmbH
TVM Capital Life Science
Dr. Marengère is responsible for TVM Capital Life Science’s overall investment strategy and global fund operations.
Dr. Marengère joined TVM in 2012 and has 23 years of venture capital experience. He was a key driver of the implementation of the TVM LSI I investment strategy which resulted in a number of investments. He is a Director on the Boards of Emovi Inc.; Acanthas Pharma; Occelaris Pharma; Ixchelsis; PRCL Pharma; Panthera Dental; FAAH Pharma; Kaneq Biosciences; Acer Therapeutics as well as Rapid Micro Biosciences. Luc was on the Board of Colucid Pharma Inc. and Aurka Pharma which were recently sold to Eli Lilly for US $960M and US $575M respectively.
Dr. Marengère brings a significant track record to TVM given his long standing experience as a Venture Capitalist. Very notable deals during Luc‘s previous tenure as Managing Partner at VG Partners include Cytochroma Inc. (sold to Opko for US$ 400M); VisualSonics (sold to Sonosite for US $75M) and CITA Neuropharma (sold to Vernalis Plc for US$ 85M). Prior to joining VG Partners, Luc focused on making venture investments in the life science sector while at La Caisse De Depot‘s venture capital group SOFINOV as well as MDS Capital and MedTech Partners.
Prior to his venture capital career, he conducted commercially-oriented research in the fields of immunology and oncology while at Amgen. Luc holds a Ph.D. from University of Toronto‘s department of Medical Biophysics and Molecular Genetics.
Mr. Sym-Smith is attending the Emerging Medtech Summit to identify new investment opportunities and scout the future of medtech.
David Sym-Smith, is a Partner at Mobility Ventures who is a 25 year mobile industry veteran with a solid record of building multi-million dollar operations from scratch along with profitable exits. Most recently, David served as Interim CEO at IndoTraq, the developer the fastest and most precise wireless indoor 3-D tracking system.
David has served as senior executive of global corporations as well as at multiple startups. He has a proven record of success in launching new markets, turnarounds, starting new business groups, building sales channels, introducing new products and services, winning market share and exceeding revenue and sales goals.
Prior to joining Mobility Ventures, David served as the Chief Strategy and Marketing Officer of Tele Atlas. David managed global marketing, strategic planning, and product development for this leading global provider of digital maps and location content. Company doubled in size and was sold to TomTom for over $3 Billion. Previously David served as the SVP of Global Business Development and Marketing at InnoPath, where he managed global marketing, product development and business development for InnoPath the industry leader in over-the-air (OTA) software updates and mobile device management (MDM) solutions. He Increased market share to 70% and revenue by more than 100%. David also helped launch Command Audio Corporation as Senior Vice President of Global Sales and Marketing, successfully leading the company from beta to launch to spin-off, growing the company from 20 to over 100 people with over $80M in funding from Tier 1 VC’s and strategic investors (partially acquired by iBiquity).
David was a member of the founding core management team of Aerial Communications, serving as Regional President; he helped grow the organization from a mobile telecom start-up from early pre-launch phase, to a large entity with a $1.1B market cap within one year and was sold thereafter for more than $3.0B to T-Mobile (VoiceStream). At Sprint Spectrum he led Marketing and Product Development in launching the first PCS network in the country and first GSM network in the Americas. Helping build a startup into an 800-employee, $150M revenue business in only the second year of service, and exiting with Sprint PCS’s purchase of operating control
David has also held senior management positions at CellularOne, AT&T, GTE, Saint-Gobain (France) and The Hay Group. He holds an M.B.A. from Pennsylvania State University – Smeal College of Business.
Simon joined Sofinnova in 2021 after consulting for Corporates seeking to develop partnership with Digital Health companies. He worked closely with business development functions to identify, assess, and structure strategic investments. Prior to that, Simon was at Baxter International, where he was part of the External Innovation Department. At Baxter, Simon coordinated scouting activities and technical due diligence that assessed M&A opportunities.
He is a Board member at Gradientech AB, a privately held Swedish company developing ultra-rapid treatment decision tools for antibiotic susceptibility testing. He is also a Steering Committee member of the MedFIT conference, an international event that brings together key innovators in the MedTech, diagnostic and digital health sectors.
Simon enjoys constant exposure to novel technologies, curious and motivated people, and supporting the development of companies that are striving to improve medicine. He decided to join Sofinnova because of the strong team spirit and collective drive.
He has a B.Sc. in Biomedical Science from King’s College London and an M.Sc. in International Business from SKEMA Business School.
Christian Snyder earned his BA in Finance and Investing from the University of Tennessee at Chattanooga while playing middle linebacker. Using two more years of eligibility, he now pursues an MBA with a concentration in data analytics, with plans to study for the CFA. Since joining Solas, Christian has provided expertise about the SPAC markets and financial analytics of current portfolio companies.
VP of Strategy & Corporate Development
Palette Life Sciences
Joshua Eckelberry graduated with honors from East Tennessee State University with a BS in Biochemistry as a Mayme Frazier Scholar and then attended Quillen College of Medicine for two years on the nationally ranked rural health track before diverting to pursue an MBA in Healthcare Administration. While in school he pioneered Quillen's anatomy lab internship where he helped create the school's first digital dissector, served as president of the local American Medical School Association, helped negotiated a hospital staffing contract worth over $1M, and raised over $200K for area non-profit clinics. With his understanding of both the science and business sides of the life science industry, Josh helps translate and negotiate the optimal outcome for patients and the companies. Josh has a lifelong commitment to drive positive impact on the community and the world through leveraged change.
Co-Founder & Managing Director
Dave has worked with the partners of Solas BioVentures since 2004 and was a founding member of the firm in 2014. He currently focuses on investments in medical device and therapeutic companies. Board certified in Maternal-Fetal Medicine, Obstetrics and Gynecology, and Hypertension, with special expertise in Critical Care, Dave is a long-time physician, educator, administrator, innovator, and biotech/med-tech investor with nearly 20 years of experience in angel and venture investing. Dave recently retired from his position as Professor and Vice Chairman of the Department of Obstetrics and Gynecology at the University of Tennessee College of Medicine. Dave also retired from clinical practice after a 30 year career. Dave received a BS in Biology from Morehead State University, where he is Hall of Fame member, is a recent graduate from University Tennessee Chattanooga with his Master of Business Administration with a concentration in Healthcare and earned his medical degree from the Joan C. Edwards College of Medicine at Marshall University in 1990. He completed residency at the University of Florida Health Science Center and Fellowship training at Wake Forest University.
Director, Software and Sensors - VELYS Digital Surgery (Global Strategic Marketing)
Johnson & Johnson
David has over 35 years of experience in corporate management, audit and finance, the last 25 years in the MedTech sector. He is an experienced MedTech investor and entrepreneur. He has invested in over 20 MedTech companies and co-founded and managed several European MedTech distribution companies over the past 23 years, including Regis Medical GmbH, Ovum Ventures GmbH (sold to Medtronic 2009), and Cardiologic GmbH (sold to Boston Scientific in 2002). Following Boston Scientific’s acquisition of Cardiologic GmbH, he served as Finance Controller for Boston Scientific in Germany, Austria and Switzerland. Prior to joining Cardiologic GmbH as Co-General Manager in 1996, David was the CFO of Chiron Adatomed GmbH, a German subsidiary of Chiron Corporation (NASDAQ: CHIR). Prior to that, he worked in Ernst & Young’s Munich office, advising on corporate M&A transactions. David holds a degree in Accountancy from the University of Birmingham, UK and is a member of the Institute of Chartered Accountants in England & Wales (ACA, ICAEW).
Global Head, In Vitro Technologies/Commercial GM
Triple Ring Technologies
Ryan was trained in genetics and cell biology at the University of California at Davis. Since 1988 he has worked in several biotechnology companies and as an independent biotech consultant focused on adding value to early stage therapeutic and technology efforts. Early in his career Ryan worked in teams that applied cutting edge genetic engineering technologies to advance the development of gene therapy and cellular therapeutics.
In 2002 Ryan transitioned to research and product development for biopharmaceutical instrumentation, where he held customer-facing positions related to the introduction of novel technologies. In this role, Ryan grew to be a recognized expert in label-free biosensors, presented at numerous international scientific conferences, and was invited to chair several scientific symposia. Ryan is co-inventor of five US patents, has published multiple scientific communications, developed many applications for the drug discovery market, and lead collaborations worldwide with well-known pharmaceutical research teams from companies like Merck, Amgen, J&J, Novartis and AstraZeneca.
Sr. Director, Business Development, Medical Device Unit, Kaneka US Innovation Center
Innovation & New Ventures
Pure Medtech Advisors
General Manager - Global Business Development
Director of International Business Development
Rob is a Partner at Endeavour Vision focused on investments in medical technology, digital health and diagnostics. Rob represents Endeavour Vision on the boards of Kestra Medical Technologies, Virtual Incision Corporation, InBrace, Willow and Nalu Medical. He serves as a board observer for IntelyCare, and was on the deal team for the investment in Rapid Micro Biosystems.
Rob joined Endeavour Vision after 15 years at Boston Scientific, which has been one of the most active acquirers in medical technology in recent years. In his role as Vice President, Corporate Business Development, Rob was responsible for leading the identification, assessment and execution of Business Development transactions for Boston Scientific’s Interventional Cardiology, Peripheral Intervention and Rhythm Management divisions. This included acquisitions, divestitures, minority investments and joint ventures.
Prior to his Business Development role, Rob held leadership positions in commercial strategy and marketing at Boston Scientific. Rob also previously worked at The 3M Company where he was an Engineering Project Leader.
Rob holds a BS in Chemical Engineering from Northwestern University and an MBA and a Masters in Engineering Management from The Kellogg School of Management.
Senior Vice President
Chairman and CEO
Alfred Mann Foundation
Robert J. Greenberg, M.D., Ph.D., is the Chairman and CEO of the Alfred Mann Foundation. He was a co-founder and former CEO and Chairman of the Board of Second Sight Medical Products, Inc. (NASDAQ: EYES) in Los Angeles, California. Dr. Greenberg is a leader in the field of neural prosthetics – having developed and brought to market the world’s most advanced implantable neural stimulator, the Argus II visual prostheses, to treat retinitis pigmentosa, a form of blindness. Dr. Greenberg was also a medical reviewer at the FDA’s Office of Device Evaluation. Dr. Greenberg is the recipient of numerous honors and awards, has over 260 issued US patents and over 100 international patents, and has published over 60 articles. He received MD and PhD degrees from The Johns Hopkins School of Medicine in Baltimore, Maryland. Dr. Greenberg joined AMF in 2004 as Chairman of the Board of Directors.
Senior Vice President, Corporate Development
Edward Hanlon joined Gilde Healthcare in 2020 in the Cambridge office and focuses on Healthtech.
Prior to joining Gilde, Edward worked in advisory for Health Advances, a consulting firm operating across healthcare sectors in medical devices, biopharma, health technology, and diagnostics. He has broad experience in commercial strategy and M&A due diligence, advising a range of clients including late-stage start-ups, multinational corporations, and financial investors. Since joining the Gilde Healthcare, Eddie has contributed to several investments, including Eargo, Spire Health, and Nalu Medical.
He has a B.S. in biology from Duke University. During his undergraduate years, he worked as a research assistant at the Duke University Center for Cognitive Neuroscience and the Liberty Mutual Research Institute Center for Behavioral Sciences. Edward is a US citizen.
Goodwin Procter LLP
Kristin Havranek has worked extensively with and in the MedTech industry for the last 25 years. A trusted advisor to investors and companies alike, Ms. Havranek regularly helps startup and emerging MedTech companies build their IP portfolios in a strategic, thoughtful manner with their business goals and needs in mind. She evaluates freedom-to-operate, patentability, investor due diligence and financing IP, and conducts patent validity analyses. She advises on strategic alliances and prepares and prosecutes patent applications before the U.S. Patent and Trademark Office. Ms. Havranek’s ties in the industry run deep and is currently on the leadership team of MedtechWomen.
Ms. Havranek’s background as a Biomedical engineer in industry, most recently as a Senior Engineer at Guidant Corporation, and as a MedTech attorney advising companies in a wide variety of technological areas makes her uniquely qualified to find the path to successful IP protection and value creation for your MedTech company.
James Huie is a corporate and securities partner in Wilson Sonsini Goodrich & Rosati's San Francisco office, where he has one of the most active practices in the country representing venture-backed companies. He advises life sciences and technology companies on general corporate matters, mergers and acquisitions, initial public offerings, strategic partnerships, and private equity and debt financings. He also has extensive experience in representing venture capital firms and other investors in private equity and debt financings.
James also serves on the investment committee for the firm's affiliated fund, the WS Investment Company.
Mr. Julian’s role involves supporting investment decisions, portfolio company management and investment outcomes. He evaluates potential new portfolio company targets with emphasis on bottom-up valuation analysis and deal structure. In addition to these responsibilities, Mr. Julian is a member of the Firm’s research team, participates in its Investment Committee meetings and is regularly evaluating thematic industry opportunities.
Prior to joining the firm, Mr. Julian was an analyst at the hedge fund Round Table Investment Management, LLC where he was the youngest member of the firm’s investment committee. His duties included security analysis, industry assessments and derivatives trading. Prior to joining Round Table, Mr. Julian played on the Men’s Varsity baseball team at Brown University.
As founder and head of Intuitive Ventures, I'm passionate about accelerating the future of minimally invasive care by investing globally in transformative early-stage startups across digital health, medtech, therapeutic and diagnostic domains.
Sabing H. Lee's practice includes strategic patent procurement, patent portfolio management, intellectual property due diligence and general counseling on infringement, licensing, international IP protection and post-grant proceedings. Sabing currently represents clients in a wide range of technologies, with an emphasis on medical devices and procedures and materials science.
Sabing co-chairs the firm’s Medical Devices and Procedures group. In the medical device field, Sabing has worked extensively with cardiovascular, orthopedic, wound care and healthcare AI technologies. He has been involved in the intellectual property strategy and acquisitions of PercuSurge, Inc. (acquired by Medtronic, Inc.), Flex-Foot, Inc. (acquired by Össur hf.), Endius, Inc. (acquired by Zimmer Holdings, Inc.), ev3 Inc. (acquired by Covidien), CardiAQ Valve Technologies (acquired by Edwards Lifesciences), and Tornier/Wright Medical (acquired by Stryker).
Sabing currently serves on the Board of Directors for Octane, an organization that drives technology industry growth and innovation in Orange County by connecting ideas and people with resources and capital.
Sabing has been recognized as a Patent Star in Managing IP's "IP STARS" guide for his outstanding intellectual property legal work in 2018-2021. He has received "Star" recognition in the "Life Sciences Survey" published by Legal Media Group (LMG) Life Sciences from 2012-2017. He was noted as being among the top patent strategists in the country for his patent prosecution, patent advisory, strategy and management practice. Sabing was selected for inclusion in the "Southern California Super Lawyers" list for his work in intellectual property law from 2013-2018 by Super Lawyers magazine, and was named to the Daily Journal's list of the "Top Intellectual Property Attorneys of 2014", where he was recognized among the Top 25 Portfolio Managers & Patent Prosecutors of Intellectual Property.
Sabing joined the firm in 1997 and became a partner in 2003.
Executive Vice President and Managing Director
Steve Pacelli is Executive Vice President and Managing Director, Dexcom Ventures.
In this role, Steve is focused on investment opportunities in sensing technology, data analytics, remote patient monitoring and population health, broadening Dexcom’s commitment to advancing better outcomes in healthcare.
Prior to this role, Steve was Executive Vice President of Strategy and Corporate Development from 2012 to 2021. Since joining Dexcom in April 2006, Steve has served in roles of increasing responsibility, including Chief Operating Officer, Chief Administrative Officer, Senior Vice President of Corporate Affairs and Vice President of Legal Affairs.
Prior to Dexcom, Steve served as a corporate attorney specializing in finance, mergers and acquisitions, and general corporate matters, and in an executive role as general counsel of several privately held companies.
Steve currently serves as a member of the Board of Directors of Biocom California, the largest and most experienced leader and advocate for California’s life science sector. He also serves as a member of the Board of Directors of Connect, a community nonprofit supporting innovators and entrepreneurs in Southern California by providing access to investors, mentors, and education, and as a member of the Board of Directors of EvoNexus, California’s leading non-profit startup technology incubator.
Steve is also a dedicated philanthropist, choosing to focus his efforts as a member of the Board of Directors of Big Brothers Big Sisters of San Diego, an organization dedicated to creating and supporting one-to-one mentoring relationships that ignite the power and promise of youth. He also serves as a member of the Board of Trustees of Pacific Ridge School, a group of dedicated and informed community leaders who are passionate about the value of education and are committed to building and strengthening the school.
Steve earned a Bachelor of Arts from the University of California, Los Angeles, and a JD from the University of Virginia. He is a member of the State Bar of California.
Alexander is a Partner at Endeavour Vision, investing in medical technology, digital health and diagnostics companies across multiple therapeutic areas.
Alexander brings more than two decades of business and strategy experience in both medical device and high-technology companies. He currently represents Endeavour Vision on the boards of Kenbi, Relievant MedSystems, Lumeon, Rapid Micro Biosystems (NASDAQ:RPID) and VentureMed, and led the firm’s investments in Gynesonics, Nuvaira and V-Wave. He previously served on the boards of VertiFlex (acquired by Boston Scientific in 2019) and EndoStim. He is a member of the steering committee for PCR Innovators’ Day and serves as both a jury member and expert panelist for the Healthtech Summit.
Prior to joining the Endeavour Vision team, Alexander spent nine years with Biosensors International Group, an interventional cardiology company, where he served as vice president of business development. He previously worked with LogiSpring Ventures, MicroStrategy and McKinsey & Co.
Alexander holds an MBA from INSEAD and a BSFS, magna cum laude, from Georgetown University
Senior Director Business Development
Collaborative leader known for results-driven, hands-on business partnership and problem solving.
Strategic thinker with a passion for utilizing strong analytical skills to challenge and improve the status quo, and a track record of delivering results with integrity and an attention to detail. Highly accomplished professional with experience in driving strategic top-line growth and profitability.
Matthew's professional experiences include work in business development and M&A, corporate finance, valuation and modeling, market strategy, tax strategy and planning, and equity research.
Specialties: M&A Experience; M&A Due Diligence; Strategic Planning; Business Strategy; Financial Modeling; Capital IQ; Microsoft Office: Word, PowerPoint, Excel, Visio, Access; Cognos; SAP; Corptax; Accounting; Financial Analysis
Matt Wetzel is an experienced health care fraud and abuse and compliance lawyer. He provides strategic advice to life sciences companies on complex health care laws and regulations, including federal and state fraud and abuse laws, billing and reimbursement regulations, and transparency requirements, among other areas. Mr. Wetzel also establishes and aids clients in operating effective compliance programs.
Mr. Wetzel brings a unique, 360-degree perspective of the legal and compliance issues affecting life sciences companies. As a veteran of the medtech industry, he brings a pragmatic approach to counseling his clients. Prior to joining Goodwin, Mr. Wetzel served as Chief Compliance Officer of a Silicon Valley biotech start-up; was the Vice President & Deputy General Counsel of the world’s largest medical technology trade association in Washington, DC; and held an executive legal role at a multinational medical device maker.
Dr. Nick Pliam joined Decheng Capital at its inception in 2011 and is based in its Menlo Park office. Trained as an orthopedic surgeon and endocrine physiologist, he leverages a combination of scientific, clinical, entrepreneurial and investment experience to build and support life science companies. He currently serves on the boards of CardiMED, Centricity Vision and Polares Medical.
Dr. Pliam was previously a venture partner at Bay City Capital, serving on the board of Nevro (NYSE: NVRO), which was incubated at Bay City to become a global leader in neuromodulation for chronic pain management. He was also a board member of Aragon Surgical (acquired by Aesculap) and IDev Technologies (acquired by Abbott). Dr. Pliam has served as an advisor to several pharmaceutical and medical technology companies, and as managing director of a New York-based boutique investment banking firm. He co-founded of Pharmagenesis, which focused on drug discovery from natural products, and Guided Delivery Systems (now Ancora Heart).
Dr. Pliam earned his undergraduate degree in German Literature from the University of California, Berkeley, completing year-long studies at Georg August Universität in Göttingen, Germany. He received his MD from Dartmouth Medical School and PhD in Endocrine Physiology from the University of California, San Francisco. Following general surgery residency at UCSF, he completed orthopedic surgical residency at the Stanford University Medical Center. He was a staff physician in orthopedic surgery at the Palo Alto Medical Foundation and Stanford Medical Center.
Anthony Williams joined HealthQuest in 2019. Before joining HealthQuest, Anthony spent eight years at Globus Medical, Inc. (NYSE: GMED), a multinational medical device company focused on developing products that promote healing in patients suffering from musculoskeletal disorders. He served in a variety of leadership roles during his tenure at Globus and ultimately spent the last 3½ years as President of the company. He currently serves as a board member on portfolio companies ENT Specialty Partners and 83bar, and as an observer for Magnolia, TigerConnect and Trice.
Prior to joining Globus Medical, Anthony was a partner with Wyrick Robbins Yates & Ponton LLP, a law firm based in Raleigh, North Carolina, where he specialized in corporate and transactional work for high growth life sciences companies and their investors, including public and private financings, mergers, acquisitions and other strategic transactions, and corporate governance matters.
Throughout his career, Anthony has been a frequent speaker to entrepreneurial groups, such as the Durham, NC-based Council for Entrepreneurial Development. He previously served on the board of directors of SEBIO and is currently a mentor to entrepreneurs through the Philadelphia-based Mentor Connect, a program sponsored by Ben Franklin Technology Partners and the Philadelphia Alliance for Capital and Technologies (PACT), and Austin-based Texas Health Catalyst, a collaborative initiative of Dell Medical School and the University of Texas at Austin, both of which provide much-needed mentoring to inventors and entrepreneurs.
Anthony holds a B.A. degree from the University of North Carolina at Chapel Hill and J.D. and M.B.A. degrees from Wake Forest University.
Anthony lives in Austin with his wife and two sons, with whom he enjoys hiking and traveling.
Chris Baker, MD
Dr. Baker began his med-tech career as a physician and has worked for over 18 years as an emergency physician at UCSF Benioff Children’s Hospital. He is board certified in Pediatrics and Pediatric Emergency Medicine and has special research interests in brain injury and pulmonary disease. He founded his first company over nine years ago in the ENT therapeutic and diagnostic space and has since been also consulting for other start up medical device firms. He joins Aphelion Capital as a Clinical Partner and continues to do clinical work as well.
Dr. Baker sits on the board at Aardvark Medical and Colabs Medical.
Prior to Ajax, David was an associate at Latham & Watkins LLP, where he advised emerging companies and VC and PE firms on corporate governance issues, equity financings, and M&A transactions. Before Latham, David served as a judicial law clerk to Chief Justice John Roberts (U.S. Supreme Court), Judge Brett Kavanaugh (U.S. Court of Appeals), and Judge Dabney Friedrich (U.S. District Court), and as a judicial extern to Judge Mark Wallace (U.S. Bankruptcy Court).
David received his J.D. from Harvard Law School, where he served as editor of the Harvard Law Review and graduated first in his class, summa cum laude. He received his B.S., summa cum laude, from the University of Southern California. Before law school, David led business development for The Drop Box, a documentary film that has raised over $10 million for children with disabilities through strategic partnerships and worldwide distribution.
Ronnie has more than 10 years of medical device project management and R&D management experience in both Chinese and American medical device industry. Now serving as the Partner of Mednovation, Co-founder of ONE investment club and Access technology. Recent deal includes Innovheart, Xeltis, Merion etc. Before investment banking, Ronnie was focus on R&D project and program management in both US and China Medtech companies. He had been engaged in several innovative projects including: Heart Valve stent, Drug eluting stent, inferior vena cava filter, Stent retriever and Flow diverter.
Ronnie owns more than 10 patents in biomedical engineering. He holds California professional engineer license. He has a MSc. In Bioengineering specializing in medical device from San Diego State University.
Director of Business Development
Prior to Ajax, Cason received his J.D. from Harvard Law School, where he served as editor and Business Chair of the Harvard Law Review, participated in the Harvard Innovation Lab venture incubation program, and graduated magna cum laude. Prior to law school, he was an account manager at Oracle, covering data security solutions.
He received his B.A. from Stanford University.
President & CEO
Jeff Peters is a Venture Partner with OrbiMed. Mr. Peters has over 25 years of medical device experience and currently serves as the President and Chief Executive Officer of Cardialen. From 2014 to 2017, Mr. Peters had several financial and operating consulting roles in public and private companies. Previously, Mr. Peters was the Chief Executive Officer of Anulex Technologies, a company developing minimally invasive spine therapies; he also served as the Chief Technology Officer of ev3 (now Medtronic) from 2001 2007. Mr. Peters’ prior financial roles include Portfolio Manager at Black River Asset Management, Entrepreneur in Residence at Foundation Medical, and Stock Analyst at Dain Rauscher Wessels. Mr. Peters received his B.S. and M.B.A. from the University of Minnesota.
Seasoned, results-driven leader experienced in identifying, launching, spinning-out, funding, building, scaling, and turning-around opportunities in healthcare and technology; strategy; operations; partnering; commercialization; and exits. Experience from roles including founder, VC, CEO, Board Chair, counsel, and advisor. Specialized in start-ups; enterprise incubation/creation; venture finance; developing/supporting early-stage and growth-stage ventures; turnarounds; and special opportunities.
Venture Capital/Private Equity: Knowledge from all sides of the table: generating/evaluating deal-flow; investing; building/managing companies/portfolios; structuring, positioning, leading, and executing financing, strategic, and exit transactions.
Leadership: Strategic planning/implementation, financial management, organizational/team development, mentoring, creating/aligning incentives, IP strategy, regulatory strategy, reimbursement, compliance, risk management, partnering, and structuring/executing financing, strategic, and exit transactions.
Technologies/Services: Domain expertise identifying, developing, financing, and commercializing healthcare, biomedical, IT, and convergence technologies; developing, implementing, and managing concepts, structures, programs, and alliances for healthcare delivery, management, infrastructure, service, support, and payment, including population health, ACOs, global risk, and MSOs.
Board Experience: Healthcare, technology, and other areas. Lead/mentor management/boards to develop/implement structure, process, and culture for teamwork, transparency, accountability, and performance.
Wavemaker Three-Sixty Health
Dr. Monica Jain is a practicing General/Endocrine Surgeon, a Biomedical Engineer, and a leader in Healthcare Innovation. She advises healthcare startup companies, leads numerous innovation collaboration efforts across Southern California, and is an active researcher and educator in Surgery, Healthcare Innovation, Human Factors/Ergonomics, Quality Improvement, and Leadership.
◉ Chair/Member of multiple Surgical and Innovation Society committees
◉ Surgery training, Cedars-Sinai Medical Center and UCSF
◉ MD, Boston University School of Medicine
◉ BS, Biomedical Engineering, Boston University
Wavemaker Three-Sixty Health
Kwame served at the FDA (in progressive leadership roles including Deputy Director) and was formerly the Vice President at a Danaher Corporation operating company. He is a lecturer and co-leads research on med-tech innovation at the University of California, Los Angeles Anderson School of Management.
◉ Managing Partner at MedTech Impact Partners
◉ Founder - MedTech Color
◉ Evaluated over 1,000 FDA applications
◉ MBA, University of Virginia
◉ MS Materials Science & Engineering, University of Virginia
◉ BS Physics, Lincoln University (Pennsylvania)
Action Potential Venture Capital
Suraj Mudichintala is a senior associate at APVC in Palo Alto, CA. He represents APVC on the Boards of Alpheus Medical and Axon Therapies. He was previously an investor at Arboretum Ventures, where he served as a Board observer at Allay Therapeutics, Avation Medical, Francis Medical, Health Scholars, Koya Medical, and RareCyte. Prior to investing, Suraj was an associate with L.E.K. Consulting, a global strategy consulting firm. While at L.E.K., Suraj completed ~20 engagements predominantly for life sciences and private equity clients.
Suraj graduated cum laude with a B.S. in Finance and Analytics from Boston College. Suraj previously served on the Michigan Translational Research and Commercialization (MTRAC) Oversight Committee for Medical Devices, where he provided guidance to Michigan higher education researchers on transitioning their early stage products to the private sector for commercialization.
Executive Director, J&J Center for Device Innovation
Johnson & Johnson
Senior Director, Ethicon and SCG Commercial Operations
Johnson & Johnson Services
Business leader with a proven track record in growth organizations. Experienced in creating and leading high performing teams, designing go to market plans and delivering exceptional results
Recruit, motivate, and lead highly effective sales teams. Quickly assess organizational needs, identify and recruit skilled teams to execute and exceed plan.
Experienced in large multinational companies, post launch start up as well as pre launch start up organizations.
Work cross functionally with all areas of an organization, finance, product development, engineering, marketing, etc. to ensure alignment and exceed revenue and profit goals.
Ernst & Young
Ernst & Young
Over 25 years of experience in the life sciences industry focusing on focusing on advising companies in all facets of corporate development. Mark’s experience spans major areas of life sciences including large molecule, small molecule, drug delivery, diagnostics, medical device firms, digital health, and healthcare distribution. Mark’s has led client engagements in North American, Europe, and Asia.
Ernst & Young
M&A professional providing financial due diligence services in the med tech and life sciences sectors. My primary fields of expertise include (i) buy-side transaction advisory for strategic and private equity clients, and (ii) full enterprise sales for private equity clients and carve-out / spin transactions for strategics.
VP of Business Development & Strategic Innovation
Tom Daulton brings over 30 years of healthcare leadership experience to Veranex, joining from National Dentex Labs (NDX), where he served as chairman and CEO for the past seven years and built one of the largest dental lab networks in North America. His additional experience includes key roles at medical device and healthcare services organizations with global scale, including 20 years at Baxter, Allegiance Healthcare, and Cardinal Health. Daulton was also founder and CEO of Devicor Medical Products, which acquired Mammotome’s breast care business from Johnson & Johnson’s Ethicon Endo-Surgery. The addition of Daulton will further expand extensive device experience across the Veranex executive suite.
Strategy and business development leader with scientific training and demonstrated success in working with multi-disciplinary teams to source, evaluate and develop innovative biomedical technologies that satisfy unmet clinical needs. Passionate about mentoring entrepreneurs motivated to make an impact in the healthcare space.
Experienced in technology and business development, project management, due diligence, primary market research, financial analysis and mapping out regulatory and reimbursement strategies for biomedical products.
Dr. Chris Stout
Center for Global Initiatives
Dr. Stout’s career includes business, government, and nonprofits, as well as the UN and academia. He’s traveled the world, published 38 books, won a wide range of accolades, including four additional doctorates (honoris causa), and invitations to TEDs, Davos, Renaissance Weekends…
He’s is a licensed clinical psychologist and Founding Director of the Center for Global Initiatives, a Top Rated Healthcare Nonprofit. His entrepreneurial experience is demonstrated in multiple start-ups and serving as an advisory board member, and early-money-in investor. He's been faculty in the University of Illinois' College of Medicine and Northwestern's Feinberg School of Medicine. He served at the UN and was appointed to the World Economic Forum's Global Leaders of Tomorrow and an Invited Faculty at Davos. He is the founder of GordianKnot, LLC, and is Emeritus VP of Clinical Research and Data Analytics at ATI.
Dr. Stout is a Fellow in the APA, past-President of the IPA, and is member in the National Academies of Practice. He is a best selling nonfiction author whose works have been translated into 8 languages. He has been awarded with 4 Humanitarian Awards and is in 3 Halls of Fame.
He has served as C/E/O/I/Officer. He has traveled to over 100 countries and founded a kindergarten in Tanzania. He is listed in TED-Founder Richard Saul Wurman’s “Who’s Really Who 1000: The Most Creative Individuals in America.” Purdue has named a scholarship in his honor.
Dr. Stout was educated at Purdue, University of Chicago, and Forest Institute, gaining over 24 awards and 4 scholarships and was Valedictorian of his doctoral class. He was a Postdoctoral Fellow at Harvard Medical School. He has been awarded over 40 other postdoctoral awards. He has been interviewed on CNBC, CNN, NBC, PBS, NPR, Oprah, Time, Chicago Tribune, Wall Street Journal, New York Times, USA Today, and others. He's an amateur alpinist, ultra runner, and diver. Full bio and portfolio: https://linktr.ee/drchrisstout Wikipedia: https://en.wikipedia.org/wiki/Chris_Stout_(psychologist)
Vice President, Marketing
Amanda DePalma joined FUJIFILM Sonosite, Inc. in December 2019 as Vice President of Marketing. In her role, Amanda has global responsibility for all marketing aspects of our business. Amanda brings over 25 years of experience in marketing, strategy, and sales at companies including Guidant, Abbott Vascular, Kimberly-Clark Healthcare, and Edwards Lifesciences. She has led high-performing teams in the development and launch of over 30 products and solutions. Amanda's healthcare experience spans multiple clinical areas with an emphasis on cardiology, vascular, surgical, anesthesiology and critical care. Amanda is passionate about fostering diversity in the workplace, and is actively involved in MedtechWomen and the AdvaMed Women's Executive Network. She received her BS in Marketing and MBA from the University of Florida.
Manager of Healthcare Business Development
Vice President, Corporate Development
In this role, Matt oversees all phases of the M&A process, from deal sourcing to execution.
Matt joined the Corporate Development team in 2015 and has managed numerous global M&A scale transactions, various tuck-in acquisitions, late-stage technology deals, and distributor-to-direct conversions.
Prior to joining Teleflex, Matt worked in the Audit and Enterprise Risk Services and M&A Transaction Services groups at Deloitte & Touche.
Matt is a CPA and has a Bachelors' degree in Business Administration from the Goizueta Business School at Emory University.
He is based in Wayne, PA, USA.
Level Eight Ventures
Dan has served as a principal, director, and advisor to early-stage and mature companies in the real estate, applied technology, and energy sectors. His areas of focus include green energy and resilient development. With a background in structured finance and complex transactions, Dan works directly with our portfolio companies and prospects to evaluate business opportunities and structure fund investments. A licensed attorney who formerly practiced at the global law firm DLA Piper, Dan received his BA in Economics from Swarthmore College and JD from the University of California Hastings College of the Law. Dan’s professional affiliations include the US Green Building Council and Urban Land Institute. Outside of work, while not spending time with his wife and four children, Dan can be found attempting stupidly uncomfortable and physically demanding challenges in inhospitable parts of the world.
Chief Information and Innovation Officer
Hunniwell Lake Ventures
Principal, Medtech Practice Leader
A partner (principal) since 1998, Glenn is living his "dream job" leading Deloitte's MedTech practice (devices, diagnostics, supplies and clinical/research tools) as it combines his roots as a mechanical engineer with his early consulting experience leading hospital clinical transformation programs. The med tech sector is positioned to be a substantial transformational force for the healthcare industry, harnessing the power of exponentials through sensor technology and augmented intelligence. However, it must adapt to new buying processes, higher "value" expectations, and a changing global regulatory and reimbursement environment.
A selection of Glenn's articles and whitepapers can be found at http://www.deloitte.com/view/en_US/us/Industries/1d4083c4abefd110VgnVCM100000ba42f00aRCRD.htm
Investment professional with 15+ years experience executing in business, technology, and regulatory sides of organizations ranging from Fortune 500s to start-ups to government agencies.
Currently focused on early-stage investments in medical devices, diagnostics and life sciences on behalf of 13 health systems and 462 acute care facilities across the U.S.
First Republic Bank
Commercial loan portfolio and relationship manager; structuring, underwriting and monitoring of credit facilities; Advanced quantitative, analytical and market research skills; Comprehensive financial data and business structure analysis; Extensive project management; marketing and investor relations; Fluent in English, Russian and Hebrew.
Executive Director, Life Sciences
Lisa is a senior relationship manager and strategic business partner with outstanding financial awareness and relationship management capabilities honed through extensive experience in the banking industry.
Global Editorial Marketing, Payments
Vice President, Life Sciences Relationship Manager
Builds partnerships with biotech, diagnostic and medical device companies throughout Southern California as part of the national Commercial Banking team dedicated to the Life Sciences industry.
Director, Corporate Development
Experienced Investment Banking Associate with a demonstrated history of working in the financial services industry. Skilled in Corporate Finance, Financial Modeling, Securities, Equities, Mutual Funds, and Asset Allocation. Strong professional with a Master of Business Administration (MBA) focused in Accounting, Finance, and Strategic Management from The University of Chicago Booth School of Business.
Vice President Program Management, Advanced Technology
Chair, Department of Medicine
University California Irvine
Accomplished healthcare executive with over two decades of sales and business development experience. Proven track record of providing executive leadership and generating financial results. Established and managed high performing teams via a cross functional, data driven approach. A diverse background that spans business development, client management, sales, consultant relations, organizational development, sales operations, data analytics and healthcare management consulting. Primary focus is to help companies achieve profitable growth and mutual value creation.
Joshua currently serves as Growth Officer within Fitbit Health Solutions where has oversight of enterprise initiatives and strategy across health plans, health systems, partners, government and research entities.
Prior to joining Fitbit, Joshua held leadership positions at Progyny and WebMD Health Services where he helped drive double-digit revenue growth. Joshua has a degree in Behavioral Science and Law from the University of Wisconsin, Madison, and completed executive courses at Columbia Business School.
Head of Strategic Partnerships
Health and wellness expert, speaker, author and leader who created, implemented, directed, managed and evaluated a broad range of health programs over the past 18 years. Experience with a diverse number of organizations including manufactures, universities, service industries, school corporations, health systems, and health plans. Specialize in consumer experience and well-being solutions that allow for strong strategic qualities that drive business results and brings forth a unique consumer centric experience. Skilled in market analysis and research within healthcare and well-being industry that drives new solutions and consumer experiences with higher engagement, increased total sales, and execution towards organizational goals.
My dedication, passion and enthusiasm for health and wellness, drives me daily to bring forth consumer experiences that allow each individual to be at their best.
• Specialize in multi-channel solutions for consumers and clients that provide choice and personalized options in improving overall health and well-being, leading to higher engagement rates and health outcomes.
• Developed, launched, implemented and operated total population management and stand-alone wellness offerings for employers and health plans, launching 12 unique platform solutions for health plans and wellness organizations.
• Over 6 years of experience in Agile development processes and over 15 years of experience in traditional development processes.
• Leading diverse teams to align to core organization goals and driving the team to exceed goals to support organization growth.
Partner and MedTech Practice Leader
Susan is a Partner at Health Advances, LLC, a strategy consulting firm focused on the healthcare industry where she co-leads the Medtech Practice Group. During her 20 years at Health Advances, Susan has worked on over 250 project engagements, with a wide variety of clients ranging from small start-ups to some of the largest public companies in the industry. Susan’s work with these companies has helped to optimize the value of products and technologies through extensive market evaluations, due diligence of M&A opportunities, and the development of strategies for sales and marketing efforts. Susan has extensive experience in the device sector, including minimally invasive and interventional products. Susan’s expertise includes women's health, urology, critical care and other hospital-based and physician office technologies. Susan has published articles in a number of industry journals including a Medtech Insight article focusing on the value proposition for medtech products and is a previous MassMEDIC board member.
Prior to joining Health Advances in 2000, Susan worked at Interneuron Pharmaceuticals, Inc. in the areas of business development, marketing, and product management. Susan’s high technology experience also includes Molten Metal Technology, Inc. Susan earned her BA in General Science with a minor in Business and Managerial Economics from Brandeis University.
Tracy Walters is a Partner in the Medtech Practice Group at Health Advances where she has worked on over 250 project engagements with a wide variety of clients ranging from small start-ups to some of the largest public companies in the industry. She partners with clients to develop growth strategies for medtech products across sites of care including hospital and physician office, and has extensive experience in many therapeutic areas including neurology, ophthalmology, and cardiology.
In 2019, Tracy summited Mount Everest, a feat accomplished by fewer than than 650 women in the world at the time.
VP, Voice of Client
Accomplished business development professional accustomed to building contacts and relationships in completely new areas. Provides client a 'Voice' during process to insure their needs are addressed and met. Helped develop client retention strategies to improve satisfaction and assure repeat business opportunities.
Rakesh J. Mehta
Rak Mehta is a founding member of the Medtech practice at Centerview Partners. He has over 25 years of experience as a strategic advisor to life sciences management teams and boards across medical device, diagnostics, and tools, and biopharma companies. Over the course of his career, Rak has engaged with clients on a broad range of complex strategic transactions, buy-side and sell-side mergers and acquistions, divestitures, debt and equity financings and partnerships.
General Inception || CEO, X-COR Therapeutics
Experienced founder CEO with a demonstrated history of working in the medical device industry. Skilled in Management, Start-ups, Financing and Leadership. Strong business development professional with a Master of Business Administration (M.B.A.) from Harvard Business School and B.S./M.S. in Mechanical Engineering from Carnegie Mellon University. 2021 Forbes Next 1000.
Chief Investment Officer
I serve as Partner for CRG, a premier healthcare investment firm that has raised and committed more than $3 billion of institutional capital across three funds to date. As a student of healthcare, I believe in developing smart financing solutions for improving patient outcomes, reducing costs and creating more personalized medicine. In my current role, I lead CRG’s investment process from sourcing and due diligence through realization and am responsible for portfolio management and portfolio company exits.
24+ years of design experience developing medical and consumer products.
Strategic leadership, management, and creative development of numerous products in a variety of industries and markets.
Chief Commercial Officer
Marketing and business development executive with extensive experience in strategic marketing, sales leadership, business development and R&D engineering within organizations ranging from mid-tier private equity owned to $30B matrixed global organizations. Proven track record for developing and launching products that drive top line revenue while improving bottom line profitability.
Founder & Managing Director
Passionate about accelerating new ventures, Nic brings 15 years of experience in leadership and advisory board roles. He has worked with companies including Medtronic, Abbott, and Philips on Product and Business Development strategy and Venture investment.
He has also advised and supported several startups in their growth, development and financing preparation.
Nic graduated with a MSc and PhD in Engineering from Imperial College London. He started his career working with Healthcare organisations including Imperial College and then NHCS Singapore as PI for Medtech Innovation. He has authored multiple patents and over 150 publications, receiving several awards for his contribution in cardiovascular innovation. He is also adjunct Associate Professor at the Duke-NUS Medical School in Singapore.
He is currently Deputy Managing Director at Medinbox, a leader in connectivity solution for medical education and remote support. He serves on the executive board of CoreAalst, a clinical research incubation company, and with DHENIN, his mission is to bring to market and accelerate disruptive value propositions that reduce costs and inefficiencies.
Chief Business Officer
Thought partner with healthcare companies globally driving strategy, business development, investments and M&A. Registered representative with series 7, 63 and 24 licenses. Most recently, Managing Director and Global Head of Medtech, of an independent strategic advisory, M&A and capital markets investment bank. Former public and private company CFO and Head of Business Development with significant leadership and management accomplishments. Eighteen+ years of investment banking experience, ten years of C-level operating experience and eight years of Private Equity and venture investing. Specialties of deep interest and extensive experience include capital markets, medical devices, interventional cardiology, precision medicine, biotech and digital health. Expertise in strategic planning, business development, corporate finance, M&A, governance, management, strategic planning and investor relations. Outside of work I volunteer and support enterprises related to empowering equality and social good.
Investor in medical devices, life science tools, diagnostics, and digital health. Feel free to drop a line if you’re an entrepreneur or investor in any of these spaces.
Hank Kucheman serves as a Senior Advisor or Board Member to various public and private medical device and health care companies. Kucheman previously served as Chief Executive Officer for Boston Scientific, focused on leading global markets for less-invasive medical devices.
Before being named CEO in October 2011, Kucheman was Executive Vice President and President of the Cardiology, Rhythm and Vascular (CRV) Group and was responsible for the Company’s Interventional Cardiology and Cardiac Rhythm Management businesses and its Endovascular Unit, which includes the Peripheral Interventions, Neurovascular, Imaging and Electrophysiology businesses.
Before joining Boston Scientific, Kucheman held a variety of management positions in sales and marketing for SCIMED, Charter Medical Corporation and Control Data Corporation. He began his career at the United States Air Force Academy Hospital and later was Healthcare Planner, Office of the Surgeon General, for the United States Air Force Medical Service.
Kucheman earned a B.S. and M.B.A. from Virginia Polytechnic Institute and State University. He has served on several industry boards, including the board of directors of the Global Health Exchange.
Divisional Vice President
I have more than 20 years of experience in the medical technology industry. My expertise is in sales and marketing and particularly in bringing innovative products and life changing technologies to market. I am passionate with new technologies and I love making a difference. I am highly result oriented and I believe that building high performing teams and developing people is essential to success.
My other passion is sailing for the challenges, the team spirit and to recharge.
Senior Director of Business Development
After completing an MBA at the Yale School of Management, New Haven, CT, in May 2014, I decided to leave the practice of medicine. I am fortunate to be able to utilize my knowledge of business and healthcare in my current role with Stryker Spine in Business Development. Prior to accepting a position with Stryker, I worked as a spine surgeon at the Montefiore Medical Center, Bronx, NY and held the title of Assistant Professor of Orthopaedic Surgery at the Albert Einstein College of Medicine, Bronx, NY. I am a board-certified orthopaedic surgeon with fellowship training in adult and pediatric spinal surgery.
VP, Business Development, Strategy, & RLM
Experienced CEO, C-level executive and Board Member with a proven track record over 24 years. The focus of my career in healthcare has been in the commercialization and implementation of medical devices and advanced technologies. My organizational experience includes well-established multinational companies as well as start-ups. I focus on organizational development through implementing structure and process.
Executive Vice President
An entrepreneurial and disciplined executive with >20 years of CEO and C-level leadership experience in health care and a track record of success in innovating, financing and commercializing sophisticated medical technology. An adaptive leader and a quick learner who has delivered results in multiple settings. Deep relationships among the investment community, industry, the medical community and government stakeholders. Extensive public speaking and advocacy experience.
Ali Golshan MD MBA
Braid Medical Group
Fellowship trained interventional radiologist practicing in a busy outpatient setting with expertise in ESRD, PAD, varicose vein treatment, interventional oncology and woman's interventions.
Health Innovation Capital
A senior principal investor and healthcare innovation, corporate finance, business development and commercial strategy executive with over 23 years of multinational experience in Venture Capital, large pharma, early to mid-market stage bio/med tech companies, and investment banking. Over his career Andrew has established himself as a proven relationship builder and deal maker across all facets of the healthcare innovation continuum, from product concept development to launching best in class treatment modalities. During this time, Andrew cultivated a successful track record for building blue chip investor syndicates, growing businesses, and originating, negotiating, and executing pharmaceutical licensing, alliances/partnerships, and acquisitions that generated significant shareholder value and tangible financial returns.
Associate Professor of Surgery
Dr. James Wall is an Associate Professor of Pediatric Surgery at Stanford University who focuses on minimally invasive approaches to children’s surgery. He is an alumnus of the Stanford Biodesign program and holds a Masters degree in Bioengineering. He has a research focus on how we educate others to design and develop health technology as well as the emerging field of surgical endoscopy. He has developed multiple health technologies including a novel epidural needle, a protection device for umbilical catheters and a wearable leg compression system. James currently leads the perioperative Value Analysis Committee and surgical endoscopy program Lucile Packard Children’s Hospital. He is the Director of Program Development for the Innovation Fellowship at the Byers Center for Biodesign at Stanford.
Vice President of Reimbursement
Innovative and proven commercial healthcare leader, experienced in strategy development, digital innovation, value-based contacting, reimbursement, and novel technologies. Successful history of developing and communicating economic value and financial impact of treatments and medical devices, for both start-ups and industry giants.
Executive/consultant to early to mid stage biotechnology, medical device and healthcare related companies on areas ranging from business/product strategy to financing. Have currently and in the past sat on the boards of several venture funded companies. Prior to my current consulting and venture projects, I was an independent analyst and consultant to institutional investors on areas ranging from satellite communications and biotech to software and new media. My research and opinions have appeared in many media outlets including Forbes, Wired, The Deal, CNN, American Banker, Barrons, Risk & Insurance Magazine, Smart Money, Reuters and Bloomberg.
Director of Business Development
Nishant has over 18 years of experience in medtech as an individual contributor and leadership role.
Currently leading the business development and investor relations at Synchron. Prior to Synchron, he has led R&D and Strategic Marketing team at medtech companies, such as LivaNova, Medtronic and Abbott.
Nishant received his Bachelor of Science in Biomedical Engineering from University of Texas at Austin and Master of Science in Electrical Engineering from Rice University. Recently, he completed the Stanford Biodesign Fellowship program at Stanford.
• Over twenty years experience in new business development, strategic marketing, and major market expansions
• Proven to excel in a position requiring strong analytical and critical thinking skill, which inspire, motivate, and guide ongoing development to empowering high performing sales and marketing teams.
• Recognized Leader of Regional and National Divisions through process reengineering, and leadership development, which increased revenue and bottom line ROI from client relationships.
• Over ten years of demonstrated expertise in developing management tools to measure and analyze financial and operational information (e.g. business trends, financial forecasting, key performance indicators, integrated budget modeling, cost analysis, and management reports).
• Ranked #1 in the U.S. for Acute Care Division Business Development in 2015 with $.75M of Total Revenue.
Specialties: Business Development, Sales Management, Strategic Marketing, Management Consulting, Medtech Startup Consulting, Identifying Market Opportunities, Strategic Mentorship, Process Improvement
I am a Vice President in Private Equity / Venture Capital at OrbiMed. Prior to this role, I was a Vice President in Equity Research at Bank of America focusing on the Med Tech industry. Prior to Equity Research, I worked in the Healthcare group at Bank of America as an Investment Banking Associate. Additionally, I worked in management consulting with Accenture Strategy focusing primarily on Operations. I received my undergraduate degree from Vanderbilt University and my MBA from Emory University's Goizueta Business School.
Justin was born and raised in San Diego, California. While attending college in Los Angeles, he began working at a medical device startup as a regulatory affairs associate and experienced multiple 510(k) and CE Mark filings. After graduating, he joined Boston Scientific Corporation as a regulatory affairs professional and worked in both the US and Japan. During this time, he worked on nearly 20 submissions for products such as carotid artery stents, neurovascular embolization coils, and coronary stents.
Upon completing business school, Justin joined Johnson & Johnson in Japan as a part of the new business development team and was in charge of assessing new technologies, managing cross-company product portfolios, and leading new projects. He also gained experience as a sales representative for the Ethicon franchise where he was responsible for over 200 Million Yen in revenue for surgical sutures, surgical drains and adhesion barriers across multiple specialties such as general surgery, gynecology, cardiology, and orthopedics.
Chairman & CEO
KYTO Technology & Life Science
Dr. Russo is the Founder & Chairman of GEO Semiconductor (www.geosemi.com) since 2014, after having served as Chairman & CEO from its founding in 2008. Dr. Russo also serves as a Director of Achelios Therapeutics (www.achelios.com), Beam Semiconductor (www.beamshaping.io), InBay Technologies (www.inbaytech.com) and several other technology and life science start-ups (Dynamount, Illuminati, Exodos and others). Dr. Russo is heavily involved with the Band of Angels and other similar organizations which review over 1,000 start-ups' business plans per year. He is also a Board Advisor to BWG, LLC. Dr. Russo has served as an outside director of ATI Technologies from 2001 through its acquisition by AMD in 2006.
Prior to founding GEO Semiconductor, Dr. Russo founded Silicon Optix in 2000, a privately held fabless semiconductor company, serving as its Chairman & CEO through 2008. Prior to Silicon Optix, Dr. Russo was the founder, Chairman and CEO of Genesis Microchip (acquired by ST Micro in 2007) following its very successful NASDAQ IPO in 1998.
Prior to founding Genesis, he was General Manager of General Electric Microelectronics Center, Senior Manager of General Electric Industrial Electronics Group and Head, Microsystems Research at RCA's David Sarnoff Research Center. While at RCA, Dr. Russo worked on the world first CMOS microprocessor and pioneered the first use of microprocessors in global communications, programmable video games, TV manufacturing automation and automotive engine control.
Dr. Russo received his B.Eng. from McGill University (Canada) and his M.Sc. and Ph.D. in EECS from UC Berkeley. He holds eight U.S. patents, is a fellow of IEEE and has received numerous RCA and industry awards, including the IEEE Centennial Medal and the 2006 Tech Pioneer Award from the World Economic Forum.
Senior Director of R&D - Digital Solutions
Johnson & Johnson
Executive Associate / Head of Managing Board Office of E. Staudinger
Senior Communications Partner to the Managing Board
A highly driven communicator with nearly 20 years’ experience and an exceptional track record in delivering business value for healthcare companies. Skilled in providing strategic counsel to senior-level executives on corporate reputation, developing strong external relationships, and cross-functional working. Deep experience working in highly regulated industries, spanning diverse and complex markets. Passionate about improving access to care for people around the world.
Chief Medical Officer & DVP, Global Medical Affairs, Vascular
Senior Vice President, Medical Technology Investment Banking
President & CEO
Rui Jing Jiang
Ms. Jiang will share the details of Avisi Technologies at the Emerging Medtech Summit and be available to discuss investment and strategic partnering interests.
Rui Jing brings extensive experience in healthcare and regulation. Rui Jing gained corporate development, strategic marketing, and product management experience from working at Allergan and Sanofi, before working at JP Morgan as an equities analyst.
Rui Jing graduated cum laude from Wharton at the University of Pennsylvania with a B.S. in Economics, concentrating in Strategic Management and Finance.
Mr. Moran will attend the Emerging Medtech Summit to share the Motus GI story and discuss strategic partnering interests.
Tim has served as Chief Executive Officer since October 1, 2018. Prior to joining us, from 2015 to September 2018, Mr. Moran served as President of the Americas, ConvaTec Group Plc (LON: CTEC) (“ConvaTec”), an international medical products and technologies company, offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. Prior to his employment at ConvaTec, Mr. Moran held roles in sales, marketing and general management over the course of eighteen years at Covidien plc (“Covidien”), an Irish headquartered global health care products company and manufacturer of medical devices and supplies. While at Covidien, until 2015, Mr. Moran served simultaneously as VP and General Manager of both the SharpSafety and Monitoring & Operating Room divisions. Following the 2015 acquisition of Covidien by Medtronic (NYSE:MDT), Mr. Moran was named the Global Vice President and General Manager of the Patient Care and Safety Division. Mr. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Mr. Moran earned a B.A. in Organizational Communication at The State University of New York at Geneseo. Mr. Moran was selected as a director because of his broad commercial experience and leadership in the medical technology sector.
Elliot studied medicine at the University of Manchester before completing his foundation training at the Oxford University Hospitals.
Alongside his clinical commitments, he retains an active role in product development, bridging the gap between clinician and designer as well as running Inovus' sales and marketing operations.
Founder & CEO
Richard has 20+ years’ experience of building international businesses and has throughout his career sought opportunities for positive market disruption through technological application.
It was this desire that led him to co-found FundamentalVR to help address an age-old problem for the medical market; how to create safe, realistic, measurable spaces to learn and develop skills.
In his role as CEO Richard is responsible for building a world class team of medical, learning and technologist who together can realise the company’s ambition of creating the world’s first global, haptically enabled, low cost ‘flight simulator for surgeons’.
Mr. Tas will share the story of SentiAR at the Emerging Medtech Summit and will provide updates on strategic partnering and investment opportunities.
Berk serves as the Chief Executive Officer and President of SentiAR. Berk has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. Prior to joining SentiAR he led the development of a novel Trans-aortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, he played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology. Prior to that he served in various leadership roles at Sunshine Heart developing a first of its kind, heart failure therapy and at Boston Scientific developing several novel therapies and technologies focused in Cardiac Rhythm Management. He holds an MBA from the Carlson School of Business at the University of Minnesota and a BS in Electrical Engineering and Physics from the School of Engineering at St Thomas University.
Mr. Frick will share the story of ChemoTech at the Emerging Medtech Summit and will discuss investment and strategic partnering milestones.
ChemoTech is an R&D oriented publicly listed Life Science company based in Sweden. With more than 30 years of collected research and intellectual properties in the field of Electroporation and clinical research, ChemoTech has developed a new patent pending patient-specific Electroporation platform. A technology platform, called IQwave™, specifically designed to treat patients with larger bulk tumors that is difficult to treat with traditional cancer therapies. The first application built on this new innovative platform is already launched in India, Philippines and Kenya. The treatment protocol for this new device is called D-EECT and is used to treat none responsive Breast cancer, Head & Neck tumors and Sarcomas. Chemotech’s primary markets are India, South East Asia and Africa as patients in these markets often lack the availability to western cancer treatments combined with late diagnoses resulting in a high degree of incidence of large superficial tumor
Born 1974 (Chengalpattu India)
Education and experience: BA, Marketing and Management, Lund University.
Co-Inventor of the D-EECT Technology and IQwave™ Next generation of Electroporation Devices
20 years’ experience as CEO, Marketing Manager and Board Director in life science industry having had positions at SYSMEX, OnMeD International, Arjo AB and Getinge AB.
Current assignments: CEO & Board Director for Scandinavian ChemoTech AB
Non-Profit assignments: Member of the Advisory Board for Billion Minds Foundation 2009-2014.
Mr. Khawar will share the story of Diality at Emerging Medtech Summit and will discuss partnering and investment opportunities.
Osman obtained his MD from the University of Glasgow and his MPH from Johns Hopkins. He is a Board-Certified nephrologist with a passion for Home Dialysis. He is an experienced Clinical researcher and entrepreneur who has run several businesses in the Dialysis industry including a Clinical Research company and several Dialysis Units in San Diego. He currently serves on the Palomar Health Foundation Board.
Dr. Mitchell will share the story of Novuson at the Emerging Medtech Summit and will discuss their financing objectives and strategic partnering plans.
Dr. Mitchell is a graduate of the University of Washington and he has been designing biomedical instrumentation and devices for approximately 20 years. Dr. Mitchell has extensive experience in biomechanics (soft tissue and orthopedic), tissue engineering, instrumentation, electronics, and mechanical design.
While at the university, Dr. Mitchell managed and conducted research in multimillion dollar DARPA projects where he developed relationships with medical industry leaders. He has conducted research in biomechanics, tissue engineering, acoustic hemostasis and high intensity focused ultrasound (HIFU) for tumor treatment. Dr. Mitchell has been involved in helping HIFU gain recognition in the clinical setting and has led research teams in conducting application studies.
Dr. Wood has 20+ years of experience championing innovative clinical solutions to the marketplace, from concept to revenue.
Dr. Wood most recently held the position of Executive Vice President of Marketing and Technology for Vital Images, an innovative advanced visualization software company. Prior to Vital Images, Dr. Wood served as VP of marketing at R2 Technology (now Hologic), where she championed the development, regulatory approval and commercial release of the first FDA approved (PMA) software product for the automatic detection of lung nodules in both diagnostic and screening chest CT examinations.
Dr. Wood received her Ph.D. from the Johns Hopkins Medical Institutions, School of Hygiene and Public Health. Her Ph.D. work combined quantifying three-dimensional lung structure with changes in lung function using high-resolution CT imaging. She also holds a Master of Science degree in Biomedical Engineering from Duke University, and a Bachelor of Science in Engineering from the University of Maryland, College Park.
Dr. Wood has been issued six patents in the field of computer-aided detection and quantitative imaging; authored numerous book chapters, peer-reviewed papers, abstracts, and served as a speaker at numerous conferences in the area of three-dimensional imaging of the thorax, quantitative imaging and computer-aided detection.
President & CEO
Delphinus Medical Technologies
As President & CEO of Delphinus Medical Technologies, Mark leads a team that has created the SoftVue 3D Whole Breast Ultrasound Tomography System for use in the screening of asymptomatic women with dense breast tissue as an adjunct to digital mammography. SoftVue is a a safe (non-ionizing), comfortable (non-compressing), and reliable (operator independent) patented technology that enhances dense breast screening and identifies more cancers with greater accuracy and potentially fewer biopsies than full field digital mammography alone. Delphinus is a privately held medical technology company headquartered in Novi, Michigan and was founded in 2010 as a spin-off of the Barbara Ann Karmanos Cancer Institute (KCI).
Prior to joining Delphinus, Mark was president and chief executive officer of OptiMedica Corporation, an ophthalmic medical device company. He led the start-up venture through development and growth, successfully completed multiple rounds of financing, and oversaw the company’s acquisition by Abbott Laboratories in 2013. He began his career in the medical technology industry as a sales representative at Grieshaber and Company, Inc., where he ultimately became vice president of U.S. sales and marketing and led the company through its acquisition by Alcon. During his tenure at Alcon, he steered the tactical integration of Grieshaber and advanced to Vice President of Global Marketing and Vitreoretinal Sales.
Mark has a bachelor’s degree in marketing from Auburn University and completed the Harvard Program for Management Development. He serves as a director on the Auburn University Foundation and is on the Dean’s Advisory Board of the Harbert College of Business at Auburn.
Richard will share the story of SANA Health at the Emerging Medtech Summit and discuss partnering and investment objectives.
With an MBA in Healthcare and Entrepreneurial Studies from Wharton Business School, Hanbury went on to become the founder of Sana, a device that allows anyone to have deep relaxation and pain relief anywhere in an average of 8-10 mintues. Sana has decades of research and anecdotal data and has just complete their first internal controlled trial.
Founder & CEO
Dr. McGinley is a board-certified diagnostic radiologist. He holds a Bachelor's and Master's Degree in Mechanical Engineering and a PhD in Physiology from Temple University. He completed his residency and fellowship at Stanford University. Dr. McGinley is the founder and CEO of McGinley Orthopedic Innovations, LLC., as well as President and CEO of McGinley Manufacturing. He is also founder and CEO of McGinley Education, a company focusing on physician education of the latest techniques in interventional sports medicine. He currently holds over 100 patents.
Reinhard Krickl is the CEO of Phagenesis®. He has extensive experience in sales & marketing and new therapy development within the medical device industry, including 14 years as a “corporate entrepreneur” at Medtronic.
Alongside his industry experience he has a MBA and a MSc in Electrical and Electronics Engineering.
Lloyd Diamond, a US citizen, is a seasoned medtech executive and CEO with 25 years of disruptive technology commercialization experience in the life science industry. He most recently served as the CEO of Precise Light Surgical, a commercially ready medical device company in Silicon Valley. Prior to that, he was the CEO of Bonesupport AB, a European orthobiologic company, where he drove rapid market penetration in Europe and the US which led to a successful IPO on the NASDAQ OMX in Stockholm. Lloyd has first-hand experience in the ophthalmology segment as he was responsible for managing Lumenis’ global surgical and vision franchises. He has commercialized many other disruptive technology platforms including at Kyphon and Laserscope. Lloyd received a dual degree in Biochemistry and Marketing from Florida Atlantic University and an MBA from the Thunderbird School of Global Management at Arizona State University.
Mr. Boaz Assaf will introduce Colospan's novel solution, the company's key achievements to date and will discuss investment and strategic partnering opportunities.
Boaz is an entrepreneur with twenty years of experience in the medical device and high-tech industries. Boaz brings to Colospan a unique set of skills in sales, marketing, organizational, operational and strategic planning. Before founding Colospan, Boaz worked at Johnson & Johnson in Ethicon Endo Surgery Division and at Medport Ltd.
Boaz holds a BA in Political Science and East Asia studies from Tel Aviv University and MBA from IDC Herzliya.
Mr. Altman will share the story of CorInnova at the Emerging Medtech Summit and discuss oppportunities to invest in or partner with the company.
William provides executive management oversight drawing on 25 years' of experience building healthcare companies. Mr. Altman is a former McKinsey & Co. consultant, and co-founded two firms that grew to over $50M revenues, including one healthcare services company that grew to 500 employees. He has served on the boards of five growth companies, including a 7,000 employee NASDAQ listed company which increased its market capitalization from $0.5 billion to $1.5 billion during his tenure, when it was successfully sold. Previously, Mr. Altman served as President & CEO of Kardia Therapeutics, a regenerative medicine company engaged in developing adult cardiac stem cells for use in heart failure therapy. A native of New Ulm, Texas (pop. 500), Mr. Altman earned a B.S. degree in Electrical Engineering from Texas A&M University, an M.A. in Politics and Economics from Oxford University as a Rhodes Scholar, and an M.B.A. from Harvard Business School.
Founder & CEO
Mr. Cohen-Bacrie will share the story of e-Scopics at the Emerging Medtech Summit and will discuss capital needs and strategic partnering opportunities.
Claude is an entrepreneur in Medtech and founded two companies in the field of innovative ultrasound imaging. He was co-founder of SuperSonic imagine in 2005, and acted as executive vice president, Chief Technology Officer and Chief Operating Officer. In that role he brought the company through 4 rounds of funding and IPOed the company in 2014. The company has recently received a binding offer from Hologic.
In 2018, Claude founded e-scopics, a point of care ultrasound company, which aims at democratizing the role of ultrasound to ultimately all healthcare professionals. The company owns and develops proprietary technologies to allow dematerialization of ultrasound imaging architectures in order to put on the market, innovative devices with strong differentiation in the point of care market.
Claude was previously managing ultrasound research within Philips Research in charge of the collaboration with Philips Medical Systems. He is also former board member of Eye Tech Care, which develops High Intensity Focussed Ultrasound technology for glaucoma treatment and act as coach for several entrepreneur within M2Care.
Claude is a scientist by training, who further specialized in Signal and image processing and a thesis in Medical Imaging. His qualifications also includes an MBA from HEC, NYU Stern and the London School of Economics.
President & CEO
Randy will share the story of Exact Imaging at the Emerging Medtech Summit and will provide relevant financing and strategic partnering updates.
Mr. AuCoin is a seasoned clinical executive with broad experience in all aspects of medical device operations. He started his career developing software in a medical device start-up and quickly realized his love for early stage companies and medical devices. Randy’s career is reflective of his passion for growing early stage medical device companies and spans a broad range of operational and managerial roles. Prior to Exact Imaging, he was a key executive in three other early stage ventures, helping to grow the companies’ valuation resulting in four liquidity events including one company which was sold twice based on the fundamental technology which Randy helped to develop and commercialize.
Randy is President and CEO of Exact Imaging, responsible for the company’s strategic direction, key operations and overseeing the development and global commercialization of its ExactVu™ micro-ultrasound platform. He joined Imagistx (now Exact Imaging) in 2011 as COO. In 2013 he became President and CEO, successfully restructuring the company into a Canadian entity, driving the Company’s strategy and fundraising, and building the Company’s management and operational teams. He also architected and led the company’s multi-site clinical trial. Randy has also successfully raised over $43 million in financing.
Prior to Exact Imaging from 2003 – 2011, Randy was Vice President, Quality Assurance and Regulatory Affairs at VisualSonics (sold in 2010 to Sonosite (SONO: NASDAQ)) and was responsible for the development and execution of all quality assurance and control efforts as well as directing all regulatory affairs and clinical programs. He directed VisualSonics’ achievement of ISO 9001 quality certification within its first 2 years of operation. He also led all clinical investigations including the original efforts into successfully validating the Imagistx’s opportunity leveraging the VisualSonics technology for prostate imaging. He also contributed to the quality system that successfully delivered over 1,500 VisualSonics high resolution-ultrasound systems with an extremely high-level of quality and customer satisfaction.
From 2000 to 2003, Randy was Manager of Engineering, QA & RA at Dicomit DICOM Information Technologies (acquired by Cedara software). From 1998 to 2000, Randy was a Y2K consultant with Ontario Hydro. Previously, from 1990 to 1998, Randy worked in cardiology as a principal engineer with Biomedical Instrumentation Inc. (acquired by American Home Products and re-branded as Quinton Electrophysiology Corporation). Quinton Electrophysiology was eventually acquired by Pruka Engineering.
Manny Villafaña, PhD, Sc
Founder of St. Jude Medical, ATS, Cardiac Pacemakers
Currently CEO of Medical 21
At the Emerging Medtech Summit Dr. Villafaña will share the story of Medical 21 (his latest venture) and discuss fundraising goals and strategic partner interests.
Co-inventor of the first lithium powered pacemaker and founder of Cardiac Pacemakers, Inc./Guidant. All pacemakers now incorporate this technology.
Co-developer of the St. Jude heart valve and founder of St. Jude Medical, Inc. This is the most commonly used prosthesis in the world.
Co-inventor of the ATS heart valve and founder of ATS Medical, Inc. (now part of Medtronic)
Co-inventor of the nitinol support and founder of Kips Bay Medical and Medical 21, Inc.
Manny Villafaña is the Founder, Chairman, & CEO of Medical 21, Inc. Dr. Villafaña is globally recognized as a “Living Legend of Medicine.” He is an award-winning USA Master Entrepreneur, a member of the Halls of Fame of Minnesota Business and Science & Technology. He is the past founder of medical device companies that have transformed the industry of cardiac surgery and improved the lives of millions. Manny is also the recipient of an honorary Doctorate of Sciences degree from the University of Iowa.
Ben received a BS in Mechanical and Aerospace Engineering from the University of Virginia, where he focused on material science, biomedical engineering, and energy engineering. At the George Washington University, his work focused on new materials and 3-D printing for stem cell growth and orthopedic tissue repair. Dr. Holmes has been awarded several patents, published numerous journal articles, and contributed a chapter to the book Tissue and Organ Regeneration: Advances in Micro- and Nanotechnology (Pan Stanford Publishing, 2014). In addition to research, he has a strong record in entrepreneurship, having participated in the National Science Foundation’s I-Corps program on the local and national levels and VentrueWell’s ASPIRE program for medical device companies. Dr. Holmes has also demonstrated a strong early stage funding track record, bringing the company an National Science Foundation I-coprs grant, a Pediatric Orthopedic Society of North America research grant and most recently a Phase I SBIR award from the NSF.
Mr. Lucas will share the story of Navigation Sciences at Emerging Medtech Summit and discuss capital and strategic partnering interests.
Alan has served in senior business development and marketing positions at development stage and emerging medical technology companies for more than 25 years. He has global senior management experience enhancing investor value, including execution of successful fund raising, IPOs, private placements and cross border M&A transactions,. His experience includes work at Alira Health, EnlightenVue, Simplicity Orthopedics, Abiomed, and Implant Sciences.
New View Surgical
Mr. Klontz will share the story of New View Surgical at the Emerging Medtech Summit and discuss capital and partnering objectives for 2021.
Bryce is an accomplished global sales and marketing executive, having built and led commercial teams in the US, Europe and Asia. Most recently, Mr. Klontz was the Vice President of Commercial Strategy, Emerging Markets at Covidien, PLC where he led efforts to build commercial capabilities within the $1.5B+ Asia, Latin America, Emerging Europe, Middle East and Africa geographies. Mr. Klontz spent 14 years at Covidien in various leadership roles including Marketing Director in both the US and Europe, as well as 3 years as Vice President, Surgical Devices Business Unit, in Asia. Mr. Klontz also served as the global post-M&A integration lead for two of Covidien's most impactful acquisitions. Earlier in his career, Mr. Klontz played a pivotal role in the global launch of The CO2 Heart Laser System. Mr. Klontz received his MBA in marketing and finance from Carroll School of Management at Boston College and a Bachelor's degree from Northwestern University.
Founder & CEO
Mr. Atria will share the story of nView Medical at the Emerging Medtech Summit and will discuss strategic partnering and investment opportunities.
Cristian has consulted and worked for Fortune 100, start-up and private equity owned companies (GE Healthcare, Fiagon GmbH, HealthTronics, nView medical). With nView medical, Mr. Atria has successfully secured seed funding from private investors, successfully obtained Small Business Innovation Research grants (SBIRs) from the National Science Foundation (NSF) and built a superb team. Prior to founding nView medical, Mr. Atria worked 13 years for GE Healthcare. His last role was General Manager with Global Profit & Loss responsibility where he ran an acquired start-up in the field of surgical navigation (VTI) and integrated it with GE OEC. Mr. Atria has developed and launched three major image guidance platforms and obtained five 510(k) clearances. Mr. Atria holds two Masters of Science in Engineering from Supelec, Paris and Politecnico di Torino, Italy and an MBA from Boston University in Boston, Massachusetts.
Lishan Aklog, MD
Executive Chairman, Veris Health, Chairman & CEO, PAVmed
Veris Health, a PAVmed Subsidiary
Lishan Aklog, M.D. has been the Company’s Chairman and Chief Executive Officer since its inception. Dr. Aklog has also served as a member of the board of directors of HCFP, Inc., a financial advisory and investment firm, since its inception, and as a co-founding Partner of both Pavilion Holdings Group (“PHG”), a medical device holding company, since its inception in 2007 and Pavilion Medical Innovations (“PMI”), a venture-backed medical device incubator, since its inception in 2009. Dr. Aklog previously served as Chairman and Chief Technology Officer of Vortex Medical Inc., a PHG portfolio company, from its inception in 2008 until its acquisition in October 2012 by AngioDynamics Inc. (Nasdaq: ANGO) for $55 million.
Dr. Aklog has been a consultant to Biomet Inc., now Zimmer Biomet (NYSE: ZBH), since 2009. He previously served as a consultant to AngioDynamics, from 2012 to 2016, Edward Lifesciences Corp. (NYSE: EW), from 2007 to 2012, On-X Life Technologies Inc. from 2009 to 2012 and Atricure Inc. (Nasdaq: ATRC) from 2007 to 2016. Dr. Aklog also previously served on the Scientific Advisory Boards of numerous leading medical device companies, including Medtronic, St. Jude Medical, Guidant Cardiac Surgery (now, Maquet Cardiovascular) and Cardiovations (then, a division of Johnson & Johnson).
Dr. Aklog is an inventor on 13 issued patents and over 30 patent applications, including the core patents of Vortex Medical’s AngioVac system and the patents for a majority of the Company’s products. Prior to entering the medical device industry full-time in 2012, Dr. Aklog was, from 2006 to 2012, Associate Professor of Surgery, Chief of Cardiovascular Surgery and Chair of The Cardiovascular Center at St. Joseph’s Hospital and Medical Center’s Heart and Lung Institute in Phoenix, Arizona. From 2002 to 2006, Dr. Aklog was Assistant Professor of Cardiothoracic Surgery, Associate Chief of Cardiac Surgery and Director of Minimally Invasive Cardiac Surgery at Mount Sinai Medical Center in New York. From 1999 to 2002, Dr. Aklog was Assistant Professor of Surgery at Harvard Medical School, Director of the Cardiac Surgery Research Laboratory and an attending cardiac surgeon at Brigham and Women’s Hospital in Boston.
Dr. Aklog received his clinical training in general and cardiothoracic surgery at Brigham and Women’s Hospital and Boston Children’s Hospital, during which he spent two years as the Medtronic Research Fellow at Harvard Medical School’s Cardiac Surgery Research Laboratory. He was then awarded the American Association of Thoracic Surgery Traveling Fellowship pursuant to which he received advanced training in heart valve surgery under renowned cardiac surgeons Sir Magdi Yacoub at Harefield Hospital in London and Professor Alain Carpentier at L’Hopital Broussais in Paris. Dr. Aklog is a co-author on 38 peer-reviewed articles and 10 book chapters. He has served on the Editorial Board of the Journal of Cardiothoracic Surgery since 2006. He is a member of numerous professional societies and has been elected to the American Association of Thoracic Surgery. He served on the Board of Directors of the International Society for Minimally Invasive Cardiothoracic Surgery from 2006 to 2009 and as President of the 21st Century Cardiothoracic Surgery Society in 2011. Dr. Aklog was recognized as one of America’s Top Doctors in the Castle Connolly Guide from 2002 to 2013. He serves as Chairman of the Boston ECG Project Charitable Foundation and the New York Executive Committee of Human Rights Watch. Dr. Aklog received his A.B., magna cum laude , in Physics from Harvard University, where he was elected to Phi Beta Kappa. Dr. Aklog received his M.D., cum laude, from Harvard Medical School. The Company believes Dr. Aklog is well-qualified to serve on the Board due to his extensive experience in founding and building successful medical device companies, his distinguished career as an academic cardiac surgeon, his recognition as a thought leader and innovator both as a surgeon and a medical device entrepreneur and his widespread relationships in the healthcare and medical device communities.
Bryan will share the Pristine Surgical story at the Emerging Medtech Summit and discuss partnering and fundraising updates.
Mr. Lord works with start-ups and investors to bring new med-tech, high-tech, clean-tech, and software products to the market and to help companies scale. He has experience as an executive, entrepreneur, advisor, deal facilitator, and investor.
President & CEO
Nick will share the story of Strados Labs at the Emerging Medtech Summit and will discuss investment and strategic partnering opportunities.
Nick is the founder of his own healthcare startup, Strados Labs and a startup consultant. He has several years experience in commercialization strategy, startup business planning, and project management.
Co-Founder & Chief Science Advisor
AiM Medical Robotics
Gregory Fischer has spent his career developing innovative technologies for image-guided surgical interventions. He is a pioneer in MRI-compatible surgical robotics capable of utilizing real-time images from inside the body to guide precision robot-assisted interventions. Dr. Fischer is a Founder of AiM Medical Robotics, a company leveraging technology from his team's research to revolutionize the neurosurgery experience. Dr. Fischer is also the William Smith Dean’s Professor of Robotics Engineering at Worcester Polytechnic Institute (WPI) and PI of the Automation and Interventional Medicine Robotics Research Laboratory (AIM Lab) where his research focuses on medical robotics, specifically the use of real-time feedback to guide surgical procedures. He is Director of the PracticePoint Research and Development Center for Healthcare Cyber-physical Systems, a state-supported Medtech accelerator with advanced point-of-practice clinical testing facilities including an OR and 3T MRI suite dedicated to research and product development.
Mr. Narrow will be a presenter at the Emerging Medtech Summit and will share the story of Sonavex and discuss investment and partnering goals.
David previously worked with multinational medical device companies to commercialize their technologies and provide long-term business strategy as a healthcare consultant at Health Advances LLC. Narrow earned his B.S. in Biomedical Engineering with Highest Distinction from the University of Rochester before receiving his Masters from Johns Hopkins University. Narrow was named 30 Under 30 in Healthcare by Forbes in 2016 and 40 Under 40 by the Baltimore Business Journal in 2017.
Dr. Eibl is responsible for the growth and development of technology, intellectual property and business strategy. Dr. Eibl holds a PhD in Biomolecular Sciences and he has conducted postdoctoral training in the field of bioengineering.
Mr. Biggins will represent Access Vascular at the Emerging Medtech Summit and will be available to discuss investment and strategic partnering objectives.
After shadowing physicians at a Boston Hospital and witnessing complications first-hand, James was compelled to design a better venous catheter. Before founding Access Vascular, James held product development, engineering, and clinical affairs roles at Ocular Therapeutix, Boston Scientific, and Medtronic, bringing over a dozen products from concept to commercialization.
Micro Interventional Devices
Mr. Whitman will share the story of Micro Interventional Devices at Emerging Medtech Summit and will discuss strategic partnering interests.
Michael Whitman is the founder and CEO of Micro Interventional Devices, Inc. (MID). Michael has over 30 years of medical device experience at market leading firms including, Johnson and Johnson, Olympus, Synthes and Power Medical Interventions. He previously was the founder and CEO of Power Medical Interventions (NASDAQ; PMII), which was acquired by Covidien Ltd. in 2009. Prior to founding PMI, Michael served in numerous management positions at Johnson and Johnson during his 13-year tenure including Vice President of Sales, Director of Sales and Marketing, Product Development and Product Management. He is the named inventor on over 35 US and foreign patents. He received his A.B. in Business and Economics from Lafayette College and completed graduate work at Wharton, University of Michigan, Harvard Executive Education, and Rutgers University.
Mr. Goel brings 15+ years of experience in medical device software/hardware design, specializing in the development of novel imaging, visualization, and analysis systems for vascular surgery. Working closely with surgeons, he developed a keen understanding of current clinical challenges and unmet needs, leading him to invent the IOPS™ technology.
Mr. Liu will share the Vena Vitals story at the Emerging Medtech Summit and will discuss investment and strategic partnering opportunities.
Ray is an executive leader in healthcare technology, with expertise in building, launching, and running products and services for both startups and multinationals. Prior to Vena Vitals, he ran product and operations for Ediom, where he created hospital decision support tools that led to the company's acquisition by Vizient, Inc. Ray also led product for Socialwellth, where he directed the development and launch of a consumer health engagement platform that was rolled out to 15.2M users, leading to the company's acquisition by Cigna.
At Siemens, Ray developed strategies, turnaround plans, and new market entries for the healthcare, energy, and industrial business units, and at GE Healthcare, he led the global launch of patient vital sign monitoring devices from China to the rest of the world. In addition to co-founding and running Vena Vitals, Ray also serves as an advisor to MDstewardship, a telemedicine company focused on antimicrobial stewardship. Ray holds an MBA from Harvard Business School, an MS from the University of California at Berkeley, and a BS from the University of Illinois at Urbana-Champaign.
CEO & Co-Founder
Mr. Shah will share the story of Nephrodite at Emerging Medtech Summit and will discuss partnering and investment opportunities.
Dr. Nikhil L. Shah currently serves as the System Chief for Minimally Invasive and Robotic Surgery at Piedmont Health Care based in Atlanta, Georgia. Dr. Shah has performed thousands of minimal access and robotic procedures with specific expertise in Genitourinary Oncology and urinary tract reconstruction. In addition, his interest and expertise in digital Surgery, intelligence, advanced-integrated imaging as well as automation as they apply to the patient-care continuum define his passion as a progressive Physician Leader.
Dr. Shah completed his undergraduate training at the University of Michigan and Medical School at the Kirksville College of Osteopathic Medicine. In medical school, Dr, Shah received a highly coveted research award funded in part by the National Institutes of Health. His training in General Surgery was at the Henry Ford Hospital in Detroit and followed with subspecialty training in Robotics, Laparoscopy and Urological Oncology at the Vattikuti Urology Institute at Henry Ford Health Systems in Detroit. During residency, Dr. Shah additionally completed a National Institutes of Health - National Institute of Diabetes and Kidney Urologist-Scientist Research Fellowship at the University of Michigan in Ann Arbor. Concurrently to his time in the laboratory, he completed a Master’s degree in Health Management & Policy at the University of Michigan’s School of Public Health and the Ross School of Business.
Dr. Shah is the recipient of numerous awards and has authored many peer-reviewed publications. He is acknowledged as an established leader in minimally invasive surgical applications. He holds an adjunct Associate Professorship at the Georgia Institute of Technology. Dr. Shah has made several appearances on CNN with Dr. Sanjay Gupta regarding Robotic Surgery and Men’s Health. In addition, Dr. Shah serves as an active advisor to the medical technology industry and the financial sector involved with innovative technology, medical devices, simulation and new surgical training applications.
Dr. Shah’s continues translational efforts by bridging the gap between health care issues, science and medicine. He speaks about the changes in health care from the perspective of a Physician Leader focusing on improving quality through metrics, analytics and outcomes analysis. Dr. Shah also continues to receive extramural funding in an effort to increase complimentary, preventive and advanced technology therapies to his patients.
Dave is the co-founder and CEO of Alio, a wearable medical device company dedicated to improving the lives of those living with dialysis and other chronic conditions. After serving in the Air Force, Dave was selected for a fellowship which allowed him to attend medical school. He received his medical degree in osteopathic medicine (D.O.) and was preparing for a surgical residency when he experienced first hand the need for better technological solutions for those with chronic conditions. Drawing on his experience as a former NIH researcher, Dave began to explore the potential of noninvasive wearables for conditions like End Stage Kidney Disease (ESKD). Since then, Alio has secured $53 million in funding to-date and formed key strategic partnerships with organizations like the NHS in the UK and US Renal Care. For more information visit www.alio.ai or follow us on Linkedin.
Chief Strategy Officer
Ted Bird has over 35 years of global commercial experience in the medical device arena, including 30 years in the spine industry specifically. He led global marketing, medical education, and business development at Medtronic Sofamor Danek, served as VP of Spine Arthroplasty Education at Depuy Spine/Johnson & Johnson, President of Orthofix Spinal Implants Division, and Chairman of the Board at Apifix. Additionally, he served as Chief Operating Officer at the Zucker Institute for Applied Neurosciences at the Medical University of South Carolina, Chief Commercial Officer at Titan Spine and founded Bird Medical Group, a strategic management consulting firm. He graduated from Brown University with bachelor’s degrees in International Relations and Political Science.
Chairman & CEO
35+ years experience in biotech/pharmaceutical industry. Led multiple companies from development stage to commercialization or M&A. Multiple Board positions.
Co-founder & CEO, Claude has more than twenty years of global experience in the Health Care industry in product & market development in pharmaceuticals & vaccines (Merck & Novartis). With extensive sales & marketing experience at the global and market level, including product launch, Claude led HPV vaccine blockbuster Gardasil regulatory, market development & commercial launch efforts. He also developed MenB vaccine, Bexsero, scientific platform, product profile & market development leading global marketing efforts through EMEA filing.
Founder & CEO
Prof Andrew McDaid is a results-driven entrepreneur, medical device executive and an internationally renowned researcher with 10+ years’ experience leading medtech companies and large R&D teams in medical robotics, wearables and AI.
Passionate about building high-performing teams.
Raised >$20M in financing from global institutions for his own technologies and businesses from basic science (including US DoD), applied R&D, through to venture capital and private equity.
Equally enthusiastic about setting strategic vision as complex tactical execution, such as go-to-market plans for new tech-enabled product-service solutions into unproven emerging markets.
Experience spanning quality, engineering, product, clinical, regulatory, reimbursement, operations as well as direct US & global sales, marketing and commercialization through strategic partnerships with large multinationals.
President & CEO
Bruce Lichorowic is a highly accomplished entrepreneur and chief executive in the medical industries.
Former Positions of Note:
- President & CEO, Trak Surgical
- Managing Director, BlueFire Capital Partners
- President & CEO, Dynaptics Corporation
CEO & Cofounder
Day Zero Diagnostics
Medical technology entrepreneur. Formerly management consultant at Monitor Group, focused on medtech commercialization, and Senior VP of Marketing & Strategy at ConforMIS. BA from Harvard and MBA from Harvard Business School.
Deep Blue Medical Advances
Mr. Perry brings 25 years of experience in medical device start-ups including having led or contributed to multiple exits, venture financings, an IPO, 16+ medical product introductions, and 20+ business development deals.
A 2013 graduate of MIT with a BS in Mechanical Engineering, Adam co-founded Vicarious Surgical in 2014 with Sammy Khalifa. Since 2010, he’s been an Emergency Medical Technician (EMT) on an ambulance in Cambridge serving the needs of the MIT community.
President & CEO
High energy CEO, Sales, Marketing, & Business Development leader with over twelve years as an International expatriate.
Strong track record of delivering results in both blue chip and early-stage companies. Expert at developing new markets, driving growth, executing turnarounds, and creating winning cultures.
History of driving rapid market penetration for new medical device technology, through: 1) field sales effectiveness, 2) strong customer development, 3) clinical economic arguments, 4) targeted physician & referral pathway marketing
- Sales, Marketing, Strategy, New Business Development
- International Growth Execution, Europe, Asia, Americas
- Sales & Field Force Effectiveness
- Physician Adoption, New Market Development
- Marketing to Physicians & Direct-to-Patients
- General Management
- Early-Stage Company Growth, Turnarounds
- Global Product Commercialization
- R&D Product Development & Manufacturing
- Organization Design to Drive P&L Growth
Peter Bloch has more than 25 years of experience in leading healthcare and technology companies in the role of Chairman, CEO and previously CFO. This includes experience in both large Pharmaceutical (Sanofi -Aventis) and earlier stage Medical Device and Biotechnology companies (Bionik Laboratories, Tribute Pharmaceuticals and Intellivax).
Dr. Marsteller is a serial medical device entrepreneur and co-innovator of the RadianceTx technology. He previously founded Salutaris Medical Devices, Inc. – invested in by ophthalmic market leader HOYA (7741:Tokyo, Market Cap $21B, $4.5B in annual sales). He is a Medical Doctor (University of Arizona College of Medicine), and physicist (Yale University Graduate School). Dr. Marsteller has Investment Banking experience as an Analyst at Lehman Brothers, and subsequently Morgan Stanley.
Matthieu De Beule
Under Matthieu’s leadership, FEops has transformed from a small academic spin-off into a fast-growing venture capital backed gazelle in the medtech sector. He completed his degree in engineering at the University of Ghent in 2002 and gained his PhD in 2008 for his research on cardiovascular device and procedure modeling.
John McDermott joined Vascular Therapies as of January 2019 as Chief Executive Officer. Mr. McDermott has 30 years of senior executive management, sales, marketing, and finance experience in the vascular industry. From 2008 to 2018 he served as the CEO of Endologix, a public company that is a developer of aortic stent grafts. From 2002 to 2007 he served as President of Bard Peripheral Vascular, a division of C.R. Bard, Inc. Mr. McDermott previously served as President of Global Sales for C.R. Bard’s vascular surgery and endovascular businesses.
Prior to that, he served for four years as President of C.R. Bard’s division IMPRA, Inc., where he was responsible for global operations, including sales, marketing, research and development, manufacturing, and finance. From 1990 to 1996, Mr. McDermott served as Chief Financial Officer and later Vice President and Chief Operating Officer of IMPRA, Inc., prior to its acquisition by C.R. Bard. He is an active leader within the vascular community and is currently on the board of directors of the International Society of Endovascular Specialists.
Mr. McDermott holds a B.S. in Finance from Arizona State University and an M.B.A from Western International University.
A serial entrepreneur and experienced leader at Fortune 500 companies and startups in the medical device, imaging, and capital equipment markets, Mr. Zemel has a long track record of raising capital and building high-performing teams to develop, launch and sell innovative new products. Prior to founding Retia, Mr. Zemel had several leadership roles in engineering, marketing and sales at a capital equipment startup and Becton Dickinson. He also authored 23 approved or pending patents. Mr. Zemel received his MS in Mechanical Engineering from the Massachusetts Institute of Technology and his MBA from the Yale School of Management.
Brian is a medical device professional who is passionate about improving clinical outcomes and healthcare costs through smart innovation. He has over 10 years of experience innovating, developing, and commercializing new class II and class III medical device technology. He previously worked in leadership positions in the Research and Development organization of the Diabetes division at Medtronic. Before joining PercuSense, Brian was the Engineering Director, Product Development, responsible for the development and commercialization of Medtronic’s Continuous Glucose Monitoring (CGM) technologies. In this role, he led the product development and algorithm development teams. Brian has significant expertise in the design, development, and commercialization of medical technology. He has managed and led large product development teams and teams focused on algorithm development and analytics. He also has significant experience on the quality, regulatory, clinical, and operations aspects of medical device development. Brian has a bachelor's degree in Biomedical Engineering from the University of Southern California and a Master's in Business Administration from Stanford University.
Patrick is passionate about leading a team and organization dedicated to supporting healthcare professionals in the area of surgical oncology. Prior to Onkos Surgical, Patrick was Executive Vice President of PDI and President of PDI Healthcare where he was responsible for oversight of strategic initiatives as well as financial performance of the Healthcare Division.
Prior to joining PDI, Patrick developed a passion for the advancement of surgical oncology in multiple roles in R&D, Marketing and General Management with Howmedica (division of Pfizer) and Stryker. In his early days at Howmedica, Patrick was responsible for the development of and launch of the company’s first FDA cleared product offering in orthopedic oncology. Patrick also holds implant and instrument design patents in orthopedic surgery.
President & CEO
30+ years of healthcare executive leadership with accomplished track-record commercializing medical devices, drugs, and drug-device combinations
Progressive leadership at private, public, small start-up to multibillion-dollar organizations in the Medical Technology and Pharmaceutical industries
CEO of private and public companies with extensive board management and capital raising experience in the private and public markets
Minimally invasive general surgeon with more than 10 years of clinical experience. Medical inventor with multiple patents and clinical researcher with publications in international journals, especially in the field of post-operatory pain.
Chief Operating Officer / Member BOD
Cephasonics Ultrasound Solutions
Randy heads our overall operations, marketing and sales. He has broad experience in technology research management and previously was CEO of an Internet technology R&D company that did extensive prototyping and research for government and corporate clients around the world.
Len Pagliaro, PhD, has 21 years of experience with successful commercialization of biotechnology products, services, and licensing, following an academic career. He has managed R&D and business development teams, and brought product lines from concept through commercialization to acquisition. A small molecule oncology project he led was successfully partnered with TopoTarget, and is now in the clinic. Len managed the P&L for a business unit of Thermo Fisher Scientific selling tools for drug discovery before co-founding Siva. He is responsible for overall corporate strategy and financing.
- 14 years in Engineering, Product Development and Management Consulting
- Sales and Marketing Transformation for Fortune 1000 companies.
- PwC, AMD, Cypress Semiconductor
Thorsten Waloschek, MBA is an experienced executive from industry with a passion for bringing new and innovative products to market that have a positive impact on patients, their families and clinicians.
Synova Life Sciences
John Chi is CEO and founder at Synova Life Sciences. At Synova, John has authored one issued patent and one pending on the matter of stem cell harvesting. In the lab, John has directed stem cell differentiation to create various cell types. He has also worked with recombinant DNA techniques in bacteria to splice and study genes for antibiotic resistance and drug discovery. He has served in both the private and public sectors and has led in corporate and academic environments. Prior to founding Synova, John led the College of Natural Sciences and Mathematics at Cal State Fullerton as its expert IT analyst from 2004-2010. Before joining the University, John was CTO and co-founder of post-production company, Digital Quest, Inc. until its acquisition in 2004. John received his BS in Electrical Engineering from Stanford University and his Master’s in Biotechnology (MBt) with an emphasis in Business through an integrated Cal State consortium graduate program (LA, Pomona, Fullerton).
Timothy I. Still’s background includes over 30 years of experience in medical devices and diagnostics. He has extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies. He has been directly responsible for building the commercial viability at many of his previous companies, five of which have been successfully acquired.
Timothy earned a B.S. degree in Biological Sciences from the University of California at Davis, and an MBA in Marketing and Entrepreneurship from the University of Southern California.
Wearable Artificial Organs
Dr. Gura is a nephrologist with more than 50 years of clinical and research experience. He is a worldwide expert in dialysis technology and a clinical professor at UCLA's Geffen School of Medicine.
Jeff is a successful general manager who retired from Varian Medical Systems after 28 years to start his own consulting and financial planning business. He blends 17 years of engineering experience and 16 years of successful business management to provide unique perspectives on strategy, business leadership, new product development, partnerships and financial planning.
President & CEO
Craig Misrach is a 20+ year business executive with escalating levels of C-level experience throughout his career. From 2006-2014, Craig was the Founder, Chairman & CEO of Freedom Meditech, Inc. a diabetes medical device company he led from concept through FDA 510(k) clearance and global commercialization. Freedom Meditech completed a cross border M&A sale in November 2016 to Sinocare, LTD after Craig had helped secure ~$15M in Series A-C Financings for the company. From 2004-2006, Craig was the President & COO of EyeChem, a start-up ophthalmic diabetes medical device company he led while obtaining his full-time MBA from the Darden School of Business at the University of Virginia. Prior to EyeChem, Craig was the Controller for Silvergate Bank where he was responsible for $500M in assets and primary financial reporting responsibility to executive management. Craig is an active CPA in the State of California and started his career at Deloitte & Touche, where he audited various middle market businesses and assisted in the preparation of S-1, 10K, and 10Q filings for public companies.
Kurve Technology's Inventor and Founder. Marc was most recently the President of EES, Inc. - a high tech staffing company placing executives across the USA. EES' main focus was consulting and building executive teams from early stage through exit strategy. Marc is considered an industry expert on the formation and building of teams. Earlier in his career, Marc spent 13 years in high-tech manufacturing where he developed and invented new products and designed efficiency equipment for production manufacturing. A long-time rhinosinusitis and allergy sufferer, Marc invented the proprietary Kurve technology. He leads Kurve's business development efforts with investors and partners and guides the engineering team.
President & CEO
PhD in Biomedical Engineering, currently involved in research, development and commercialization of medical devices, with focus on monitoring of lung health specifically on anesthesia/ventilation circuits with application in diagnosis and treatment of disease.
A practicing surgeon and surgical educator, Dr. Goel currently practices in the Vancouver, B.C. area and also serves on the University of British Columbia’s Faculty of Medicine in the Department of Orthopedic Surgery. He received his medical degree from the University of Manitoba, pursued his residency training in orthopedic surgery at the University of Calgary, and completed fellowship training in shoulder surgery at the University of Western Ontario and Harvard University. Goel has co-authored more than 30 publications, and is widely sought as a presenter on surgical techniques.
Medical Physicist. 11+ years in academic research, 11+ years at GE Healthcare as Six Sigma Master Blackbelt and Physics Manager; 4 years as VP and CTO at Gamma Medica (MBI startup, sold to CMR Naviscan), and 5 years as Senior VP at Kromek (formerly eV Products, a company that manufactures MBI detectors).
I am passionate about impacting global health by leveraging my medical device and international experience to improve access, efficacy, efficiency and affordability. I believe this all starts with meaningful communication: understanding the needs and priorities of patients, practitioners, payers, governments, device creators and distributors is key to creating targeted solutions with lasting impact and financial sustainability. In addition to being an entrepreneur, I also enjoy empowering other entrepreneurs.
I am a medical device executive with over twenty-five years of leadership experience spanning quality, engineering, and operations including product line, business integrations and new product launches, six-sigma implementations for both operations and business process, and US and global marketing in surgical and monitoring environments.
My marketing experiences span business development (target identification, business case development, diligence), product development (concept through commercialization), into tactical commercial execution bringing innovative solutions to new sites. Market segments span the "admit to discharge" care continuum including the highest acuity in the OR/ICU through terminal chronic care and home care environments.
My experiences are built upon a four years foundation of basic science research at a premier international research institution.
James Y. Lancaster, Chief Executive Officer, is a seasoned entrepreneur and business development executive with 30 years of experience across multiple industries. He was most recently the Founder and Managing Director of the Innovate Family of Companies with client technologies including a variety of software, innovative materials, internet-of-things, robotics, autonomous vehicles, drone technologies, medical device, biological control, and waste recycling technologies. Prior to becoming an entrepreneur, he worked for Deloitte Consulting in Dallas with Fortune 500 and held other executive positions in business software and services, medical technologies, and IT solutions.
Peter Vranes is a Chemical Engineer and serial entrepreneur. Peter is the co-founder of Nutromics, an Australian MedTech company revolutionising healthcare through continuous real time molecular monitoring. The company’s innovative Smart Patch biosensor platform will solve some of the biggest healthcare challenges we face today in the fields of chronic disease prevention, chronic disease management, acute diseases and Therapeutic Drug Monitoring.
Prior to Nutromics, Peter founded Biocore Technologies and lead the team with the development and commercialisation of several natural cosmeceutical skincare brands that were distributed in 1,500 retailers throughout Australia. The company was successfully sold in 2013.
President & CEO
Ms. Holzberger is a 20 year seasoned leader in Enterprise Imaging and Radiology. Prior to being appointed as the President and CEO in January 2022 she was the Senior Vice President and General Manager of Enterprise Imaging at Nuance Healthcare (soon to be acquired by Microsoft) leading go to market, product development and product strategy for the $190M Business Unit. Key launches included AI workflow solutions for Radiologist documentation, communication and follow up solutions. She holds an Engineering degree from Steven’s Institute of Technology and many business and leadership certificates from Harvard University’s Business School and the Stern School of Business.
President & CEO
Serial entrepreneur, Angel Investor, and Board/Advisor with a proven track record leading, growing and monetizing technology-driven companies across the full life-cycle of inception & funding to product-launch & exit. Twenty-five years of success building world-class organizations and executing "idea-to-implementation" hyper-growth strategies for FDA-regulated MedTechs, University spin-outs, Tech-company turnarounds, IoT businesses, and Disruptive Technology Innovations.
Sam Owen has spent over six years working with acoustics and acceleration sensors, leading to the development of Otolith’s patented non-invasive Vestibular System Masking (nVSM) technology. His work has played a key in developing the underlying science and initial prototyping as well as the development and execution of clinical testing to validate the technology at Otolith Labs. Sam was a Fellow at the Halcyon Incubator and earned his Master’s in Physics from Georgetown University.
Dr. John H. Wong is an associate professor in the Departments of Clinical Neurosciences and Radiology at the Cumming School of Medicine. He serves as Director of Cerebrovascular and Endovascular Neurosurgery and maintains a busy clinical practice almost exclusively dedicated to treating brain aneurysms and stroke. Dr. Wong received his medical education and neurosurgical training at the University of Alberta. After a one-year fellowship in neurovascular surgery at Yale University and further two-year specialization in interventional neuroradiology in New York City, he was recruited to Calgary in 2001. Since then, he has helped develop one of the most collaborative and productive neurovascular and stroke units in North America with colleagues in neurology, radiology, and neurosurgery.
Dr. Wong has co-authored numerous peer-reviewed manuscripts and has served on several grant review panels including for the Canadian Institute of Health Research and the National Institutes of Health in the U.S. He has held numerous local and national leadership roles including the provincial past president of the Alberta Neurosurgical Society for over a decade, previous Division Head of Neurosurgery at the University of Calgary, and is the current Vice President of the Canadian Neurosurgical Society. Dr. Wong received his MBA from The Wharton School of Business at the University of Pennsylvania where he earned a double major in Finance and Entrepreneurship & Innovation and was conferred the Dean’s Leadership Award.
Jonathan "JB" Berent is a visionary leader who is passionate about exploring human consciousness and unlocking its full potential. As the CEO and Founder of NextSense, he has combined his extensive business experience with cutting-edge scientific research to develop innovative biosensing wearables.
Throughout his executive career, JB has managed teams of more than 110 people and overseen budgets of $50M or more at public companies Oracle and Google. However, in 2016, he decided to follow his lifelong passion for exploring the connection between the mind and body and left sales and partnerships to focus on developing brain sensing technologies at X, the moonshot factory.
JB's innovative work has earned him numerous speaking engagements at prestigious universities such as Stanford and UCSF, as well as conferences such as the Chan Zuckerberg BioHub and the Stanford Medicine Big Data Health. In June 2022, he was featured in a long-read cover story in Wired magazine, which highlighted his groundbreaking work in the field of biosensing wearables.
JB graduated with Honors from Stanford University with a Philosophy and Religious Studies degree.
Executive Chairman & CEO
Howard Leonhardt is an inventor and serial entrepreneur. He has 21 U.S. patents for products for treating cardiovascular disease. His TALENT stent graft developed in the early 1990′s holds a leading world market share for repairing aortic aneurysms without surgery. His inventions have treated over 200,000 patients in 60 countries.
Sandy joined Lumeda as Chief Executive Officer to lead the company in its product commercialization and growth phase. A graduate of Harvard Business School (MBA), Mr. Zinke has over 20 years of global healthcare industry experience with innovative companies including Boston Scientific, Cynosure / Hologic and CDx Diagnostics. Prior to joining Lumeda, he was Vice President of Marketing & Business Development with CDx Diagnostics, known for an advanced diagnostic platform used to preemptively detect cancer based on AI-enabled tissue analysis and 3D imaging. Over the last 10 years he has led teams that have developed and commercialized more than a dozen products and programs. Sandy has a strong track record of success in building and leading cross-functional teams to drive global growth of healthcare companies with innovative medical device and diagnostics products. He brings to Lumeda significant domain expertise and a network of industry contacts to develop key relationships with medical thought leaders and commercial partners critical to accelerate the introduction of the company’s novel PDT technology to the clinic.
John von Benecke
John has a strong track record as an executive in a range of Life Sciences and healthcare companies, covering both pre-revenue and commercial high growth companies. He has raised more than $130m of venture capital to date and taken two start-ups through to successful exit events, including the $330m acquisition of ApaTech Ltd by Baxter. John has gained strong operational experience across a range of business functions and organisations, including fulfilling combined CFO and COO roles for two private companies previously.
John holds a Bachelor’s degree in Organisational Psychology and is a member of the Chartered Institute of Management Accountants.
EVP - Business Development/GC
Ilan, CEO of CAPS Medical, has nearly 20 years of experience in the medical device and defense industries, having held executive management positions in multiple biomedical device companies in the fields of electrophysiology, invasive cardiology, and minimally invasive implantable maxillofacial solutions. He has served in leadership positions at OSSIO, Maxillent and Perifect, contributing to these companies’ continuous growth through a deep understanding of the medical device market, strategic product development, regulatory road-map building and execution, including CE and FDA compliance and successful product rollout/launch in US and European markets. Earlier, Ilan held R&D and project management positions in Unit 81, Israeli military intelligence’s elite technology unit, where during his tenure, his teams delivered numerous technologically and operationally complex projects, playing an important role in winning the top Israeli defense prizes. Ilan holds a BSc degree in mechanical engineering, an MSc in biomedical engineering, and an MBA – all received from Tel Aviv University.
Finbar is responsible for leading, developing VERSONO’s short and long-term strategy and the overall management of the company’s operations. His role also involves developing and communicating VERSONO’s vision and mission with its stakeholders, customers, board of directors and government agencies. Finbar has over 20 years of executive and leadership experience within the Medical Device Industry and has worked with CR Bard, Medtronic, GTI, Lake Region/Integer, Arc Devices, in product development, strategic R&D and manufacturing operations.
Finbar has also contributed on a pro bono basis to initiatives in IBEC’s MedTech Ireland, the IRDG, the American Chamber of Commerce Ireland and Engineers Ireland. A chartered engineer, Finbar holds PhD, MBA and BSc degrees and is a BioInnovate fellow.
27 years of executive leadership proficiency in both medical device start-up and multinational organizations. Specific experience in C-level general management, product development, scaling, go-to-market, and commercialization, focused on the fields of respiratory, anesthesia and critical intensive care medicine
Declan is CEO and founder of Mirai Medical. He has spent over 20 years working in cancer research working in medical device and immunotherapy research. Dr. Soden has published extensively on electroporation and its development in cancer treatment leading to a number of clinical studies which have assisted in validating this exciting technology.
Inventor of the SONAS® device.
Former Professor at University of California San Diego, Departments of Radiology and Neurosciences.
Board certified neurologist.
Founder of the UCSD Brain Ultrasound Research Laboratory.
Fields of expertise: stroke, brain ultrasound, microbubbles.
Mark is a Chartered Accountant, a Chartered Director, qualified as a Corporate Treasurer and holds an MBA from Saïd Business School, Oxford University. Mark’s experience includes regional CFO roles within listed companies (CTI Molecular Imaging, Siemens Healthcare) for business up to EUR 800m, CFO roles within venture-backed business, and General Management roles within medical imaging software development and radiopharmaceutical manufacture.
Mark has over 17 years of experience in medical imaging including with www.mirada-medical.com, an oncology imaging company, and as a Non-Executive Director for www.cydarmedical.com, a surgical imaging spin-out from King’s College London. Mark is an inventor on 9 patents.
CEO & VP R&D
Almog Aley-Raz has over 25 years of experience managing complex, multi-disciplinary projects. He has spearheaded the development of several business ventures, including their foundation, growth and expansion, fruition and ultimate success. Aley-Raz is CorNeat Vision co-founder and has been the CEO and VP R&D since its inception in 2016.
Mr. Aley-Raz has hands-on technological and managerial experience at several startup companies, as well as established corporations. He has handled diversified aspects such as engineering, professional services, product management, marketing, finance, legal, compliance, mergers and acquisitions. Previously, Mr. Aley-Raz served as GM and VP Biometrics and Security Solutions at Nuance Communications (NASDAQ: NUAN), directing an international team, which consisted of dozens of members. During his tenure at Nuance, he was able to grow its biometrics business line from several million USD to over $80 million/year. Nuance was recently acquired by Microsoft for ~20Bn. Mr. Aley-Raz joined Nuance in 2010 through the acquisition of PerSay, where he served as CEO. He joined PerSay in 1999 as a system engineer when the company was still a part of Verint Systems Inc. – formerly Comverse Infosys. As part of his work, he successfully raised over $11 million from the Israeli Venture Capital industry.
Before joining Verint in 1999, Mr. Aley-Raz served as a project manager – managing a strategic mission-critical 150 man-year government software project, including software and network infrastructure deployment in multiple physical sites. The project met its targets in all aspects (budget, timeline, performance) and is operational since 1999. Previous assignments included managing 35 engineers and field engineers who handled complex airborne communication and optical systems.
Almog Aley-Raz holds a BSc in Electrical Engineering and Digital Signal Processing from Ben-Gurion University and is an MBA graduate of the Leon Recanati Graduate School of Business Administration at Tel Aviv University. He completed a continued education course at the Technion (Israel Institute of Technology) in managing the development and regulation of medical devices.
Mr. Richard Hughen is a high impact executive leader, business builder with start-up, small-cap, and fortune 100 experience, innovative thinker and creative problem solver with expertise in building shareholder value, milestone achievement with unrelenting focus, leading complex, cross-functional teams, marketing strategy and business development, product development and commercialization, trial, regulatory and reimbursement strategy, international market development and launch, sales - management and operations, intellectual property and licensing, fund raising - equity and debt, licensing and intellectual property.
CEO & co-founder
Over 25 years experience in managing and shaping businesses in the medical field, covering general commodities, services and medical devices in the fields of cardiology, renal therapies, neuromodulation and orthopedics. Head of AF Solutions for Medtronic in Europe/ Asia, with responsibility to integrate Cryocath Laboratories and Ablation Frontiers acquisitions into the Medtronic AF portfolio.
Proven experience in establishing new businesses. Entrepreneurial and strategic attitude towards identifying and exploiting opportunities and strong leadership in implementing value driven plans. Good track record in the development and launch of new products, exploring new businesses, business models and setting up multiple channels of distribution. Experienced in negotiating with high ranked government officials, c-suite and negotiating mergers and acquisitions.
Strong and effective leader in coordinating projects across all functions, including engineering, R&D, clinical, regulatory and finance.
Start up, small/medium (PME) enterprise coach and mentor.
B.S. degree in Pharmacy-Biochemistry and Masters in Industrial Administration and MBA from the University of Sao Paulo Brazil
Syntr Health Technologies
Mr. Zobi is the Founder and CEO of Syntr Health with over 8 years of experience in microfluidics and biomechanics, and has headed research and development, management, and grant submissions. He has successfully attained all funding and has guided the company towards 510(K) clearance and commercialization of the SyntrFuge System.
Mr. Zobi received his BS in Biomedical Engineering, specializing in micro and nanotechnology, from the University of California, Irvine, and recently received his EMBA from Quantic School of Business and Technology.
Prior to joining Alyve Medical, Yvonne was most recently a President and General Manager at Zimmer Biomet. She spent more than ten years at Zimmer Biomet in a number of leadership and executive roles of increasing responsibility, overseeing a variety of functions and, in more recent years, businesses that totaled nearly $300M in annual revenues. Prior to her time at Zimmer Biomet she served in leadership roles at Medtronic Spine & Biologics, QuadraMed, and healthcare consulting companies, preceded by several years in hospital administration. Yvonne obtained her MBA, as well as is a Fellow in the American College of Healthcare Executives.
Yvonne brings a strategic medical device background, strong P&L experience, and a leadership development approach that attracts expert talent. Her strong drive, sense of urgency, combined with outstanding communication and execution skills guide her teams to deliver strong results. “I could not be more excited about the potential of Alyve Medical. With first class, innovative products, and an exceptional leadership team, our future is set to skyrocket!”
Chairman & CEO
Advanced Bifurcation Systems
Dr. Khorsandi is a renowned expert of endovascular interventions. He has been performing cardiovascular and vascular interventions for over 25 years with one of the highest success rates in the field.
Dr. Khorsandi’s expertise and interests include: High Risk Coronary Angioplasty, Peripheral Artery Disease and Limb salvation, Certified Implanting Physician for Pacemaker and Defibrillator Implantation, Amputation Prevention, Varicose Vein Treatment. He has been on the attending staff at Cedars Sinai since 1993. As a member of the Cedars-
Sinai Heart Institute, he is actively involved in the training of the cardiology and interventional cardiology fellows in the cardiac catheterization lab.
- Diplomate, American Board of Cardiovascular Disease.
- Diplomate, American Board of Interventional Cardiology.
- Diplomate, American Board of Endovascular Medicine.
- Diplomate, American Board of Internal Medicine.
- Certified Cardiac Device Specialist (formerly NAPSE)
- Fellow, American College of Cardiology (ACC).
- Fellow, Society for Cardiac Angiography and Interventions (SCAI).
- Fellow, Vascular Interventional Advances (VIVA).
Dr. Khorsandi is a graduate of the University of Pennsylvania School of Medicine and completed his residency and fellowship training in Internal Medicine and Cardiology at Cedars-Sinai Medical Center.
Dr. Kambiz Behzadi is an orthopedic surgeon in Pleasanton California. His practice is primarily focused on adult joint reconstruction and sports related injuries. He has particular interest in physical sciences. His research interests include efforts to improve surgical techniques and to produce novel medical devices to enhance reliability and safety of orthopedic procedures for the ultimate goal of improving outcomes.
Dr. Tamir Wolf is the CEO and Co-founder of Theator, the Surgical Intelligence platform that allows surgeons to achieve peak surgical performance with an innovative platform built for surgeons, by surgeons, to create actionable and accessible surgical data, and use it to comprehensively analyze patient outcomes, improving surgical decision-making, boosting surgeon performance and the quality of patient care. Dr. Wolf was the valedictorian of his class at Technion, the Israel Institute of Technology where he earned his MD, PhD in Medicine, specializing in Cardiovascular Physiology. He was a Lieutenant commander in the Israeli Navy SEALs, where he served as the Head of the Unit’s Medical Branch and earned a medal of distinguished service during the 2nd Lebanon War for treating wounded soldiers under fire. Following his stint in the army, he was drawn towards a career in health technology, in part due to technology’s power to impact the lives of billions. As such, in 2013 he was the Founder and CEO of Digma Medical – a company that pioneered a new path for treating Type 2 Diabetes – as well as the Co-founder of NiTiNOTES Surgical – a company that develops safe, effective and long-lasting minimally invasive solutions for treating obesity.
Tom Ramsay is an imaging expert with more than 40 years of experience, including numerous breakthroughs in the development of technologies for a wide range of applications. Tom holds 10 patents, either granted or pending, in the domains of optics, image processing, and computer-based machine learning.
Tom is a nationally recognized imaging expert, consulting on a wide range of scientific projects for U.S.-based and global companies, including Pioneer, Sony, Matsushita, NEC, Hitachi, 3M Corporation, American College of Radiology, Radiological Society of North America, American Society of Clinical Pathologists, CDC (Asia), United Nations, Lockheed, Northrop Grumman, U.S. Department of Homeland Security, and Thomson CSF (France).
Tom’s experience also includes several senior level positions, including managing projects for Sony, NEC, Hitachi, Pioneer, and others. He has invented a wide range of technologies for image processing, optical disk recording, and the radiology community, including co-invention of the first PACS (picture archiving and communications system) for breast imaging while serving as CEO of Image PSL—an innovator in image processing and medical training in partnership with the Mayo Clinic and Yale Medical School.
Tom’s background also includes several startups organized around his inventions, including the development of technologies to create a national product imaging database for Japan; photo microscopy analysis of tuberculosis in Africa; image-based gem trading in Thailand; explosive detection through analysis of X-ray images generated by portable bomb technician systems and through analysis of images generated by X-ray scanners of carry-on luggage moving through TSA airport checkpoints; fingerprint optimization analysis for the FBI; and the restoration of Thomas Edison’s movies for the Library of Congress in Washington, D.C.
In 2013, Tom was honored with an Alumnus of Notable Achievement Award from the University of Minnesota for his contributions in medicine and image processing. He also served as a member of the Emerging Technologies Advisory Group (EmTAG), a select advisory panel of the Association for Information and Image Management (AIIM).
Tom holds a Bachelor of Arts from the University of Minnesota.
Spinal Stabilization Technologies
Mark Novotny has 28 years of experience with “Bench to Bedside” medical device innovation. During these three decades, Mark held roles across all functions of R&D, Operations, Sales and Marketing, Clinical Sciences, Regulatory and Quality. Mark has worked on numerous projects in critical care, cardiovascular and spinal surgery throughout the US, Asia and Europe. Medical device technologies he has worked on are used every day in at least 40 countries and collectively they have generated billions of dollars in sales.
Chief Medical Officer
ViTAA Medical Solutions
Dr. Moore is Co-Founder of ViTAA Medical Solutions and serves as its Chief Medical Officer. He is a Fellow of the Royal College of Surgeons of Canada and a Fellow of the American College of Surgeons and a member of the Canadian Society for Vascular Surgery, where he has previously served as the Research Chair, as well as the Society for Vascular Surgery. He has previously served two terms as President of Vascular Surgery for the Alberta Medical Association, as well as Division Chief of Vascular Surgery for the Calgary Health Region and has a cross appointment with the Schulich School of Engineering at the University of Calgary, with multiple published research studies related to complex Aortic Aneurysm Repair, Vascular Hemodynamics and Vascular Imaging.
ViTAA Medical Solutions is pioneering AI solutions within the vascular space with an initial focus on changing the standard of care for aortic aneurysm disease. With expected regulatory approval in 2024, its first commercial product RAW™ (Regional Areas of Weakness) Maps is available as part of the ViTAA Registry which has been launched in 8 North American sites as well as ViTAA’s Research Use Only Program consisting of 25 participating US Aortic Centers.
General management and commercial leader in medical devices, diagnostics, imaging capital equipment, and health care IT; US Surgical, Boston Scientific, Genzyme Genetics, Hologic, Oxford Immunotec, CRA Health.
Mr. Ghosh has extensive product development and business experience in the medical devices industry. He invented the algorithms for automating the QLSS® technique so it can be easily used by any operator. Mr. Ghosh serves as CEO. He is also President of Syprosoft, Inc. - an engineering firm. Mr. Ghosh has an M.S. in Electrical Engineering from the University of Rochester, and an M.B.A. from Marquette University.
Dr. Marc Curial is an Emergency Physician, Clinical Lecturer, and inventor with a passion for making complex concepts simple. Marc is an outgoing, democratic leader who thrives co-ordinating a multidisciplinary team in a chaotic environment. Gregarious, flexible, diplomatic, and persuasive; Marc thrives in the rapidly evolving environment of a busy urban Emergency Department.
In his role as an Emergency Physician, Marc is specifically skilled and practiced at making decisions based on imperfect information and adapting to any situation as it evolves. Always up for a new challenge, Marc thrives at building creative solutions with patients, colleagues, and co-workers.
Marc developed the concept for the MACH32 Autoinjectors after witnessing and analyzing common difficulties faced during trauma resuscitation and applying a creative concept to these problems. He started the idea for the aerosol containment tent after working as a front-line healthcare worker during the COVID-19 pandemic crisis. As the creative force behind MACH32, Marc is up to date with the current standards of practice in medical care and the many gaps still needing to be addressed by novel ideas and inventions.
In his free time Marc loves to ski, run, and cook with his wife and young sons.
15 years experience in the medical device industry as an engineer, product manager, and consultant; deep understanding of medical device development and lifecycle; MBA, Tel Aviv University, B.Sc., mechanical engineering, Ben-Gurion University of the Negev